; onclick=)
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/dabrafenib-uses-dosage-side-effects-interaction_245535.jpg?fit=800%2C600&ssl=1" class="aligncenter wp-post-image" alt="" decoding="async" srcset="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/dabrafenib-uses-dosage-side-effects-interaction_245535.jpg?w=800&ssl=1 800w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/dabrafenib-uses-dosage-side-effects-interaction_245535.jpg?resize=768%2C576&ssl=1 768w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/dabrafenib-uses-dosage-side-effects-interaction_245535.jpg?resize=360%2C270&ssl=1 360w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/dabrafenib-uses-dosage-side-effects-interaction_245535.jpg?resize=600%2C450&ssl=1 600w" sizes="(max-width: 800px) 100vw, 800px" data-attachment-id="255613" data-permalink="https://rxharun.com/rxharun/drug-a-z/dabrafenib/attachment/dabrafenib-uses-dosage-side-effects-interaction/" data-orig-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/dabrafenib-uses-dosage-side-effects-interaction_245535.jpg?fit=800%2C600&ssl=1" data-orig-size="800,600" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Dabrafenib – Uses, Dosage, Side Effects, Interaction" data-image-description="" data-image-caption="" data-medium-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/dabrafenib-uses-dosage-side-effects-interaction_245535.jpg?fit=800%2C600&ssl=1" data-large-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/dabrafenib-uses-dosage-side-effects-interaction_245535.jpg?fit=800%2C600&ssl=1" data-jpibfi-post-excerpt="" data-jpibfi-post-url="https://rxharun.com/rxharun/drug-a-z/dabrafenib/" data-jpibfi-post-title="Dabrafenib – Uses, Dosage, Side Effects, Interaction" data-jpibfi-src="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/dabrafenib-uses-dosage-side-effects-interaction_245535.jpg?fit=800%2C600&ssl=1">
Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase and is used alone or in combination with trametinib in the treatment of advanced malignant melanoma. Dabrafenib therapy is associated with transient elevations in serum aminotransferase during therapy but has not been linked to instances of clinically apparent acute liver injury.
Dabrafenib is an orally bioavailable inhibitor of the B-RAF (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-RAF, which may inhibit the proliferation of tumor cells that contain a mutated BRAF gene. B-RAF belongs to the RAF/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
Dabrafenib is an organofluorine compound and antineoplastic agent, used as its mesylate salt in the treatment of metastatic melanoma. It has a role as an antineoplastic agent, a B-Raf inhibitor, and an anticoronaviral agent. It is a sulfonamide, an organofluorine compound, a member of 1,3-thiazoles, and an aminopyrimidine. Dabrafenib mesylate is a methanesulfonate (mesylate) salt prepared from equimolar amounts of dabrafenib and methanesulfonic acid. Used for treatment of metastatic melanoma. It has a role as an antineoplastic agent and a B-Raf inhibitor. It contains a dabrafenib.
Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-RAF (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-RAF, which may inhibit the proliferation of tumor cells that contain a mutated BRAF gene. B-RAF belongs to the RAF/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
Mechanism of Action
Dabrafenib is an orally bioavailable inhibitor of B-RAF (BRAF) protein with antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-RAF, which may inhibit the proliferation of tumor cells that contain a mutated BRAF gene. B-RAF belongs to the RAF/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/Extracellular Signal-regulated Kinases signaling pathway, which may be constitutively activated due to BRAF gene mutations.
Dabrafenib causes inhibition of phosphorylated extracellular signal-regulated kinase (ERK). This indicates a decrease in cell proliferation. Furthermore, within 24 hours of administration, downstream mediators of the MAPK pathway were inhibited. The melanoma approval for use with Mekinist is based on results from COMBI-AD, a Phase III study of 870 patients with Stage III BRAF V600E/K mutation-positive melanoma treated with Tafinlar + Mekinist after complete surgical resection. Patients received doses of Tafinlar (150 mg BID) + Mekinist (2 mg QD) combination (n = 438) or matching placebos (n = 432). After a median follow-up of 2.8 years, the primary endpoint of relapse-free survival (RFS) was met. Thus, Tafinlar in combination with Mekinist treats melanoma. In the case of thyroid cancer, Dabrafenib plus Trametinib is the first regimen demonstrated to have potent clinical activity in BRAF V600E–mutated anaplastic thyroid cancer and is well tolerated. These findings represent a meaningful therapeutic advance for this orphan disease.
Indications
- Tafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Tafinlar in combination with [DB08911] is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of a durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for Tafinlar in combination with trametinib. In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
- Melanoma – Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
- Adjuvant treatment of melanoma – Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
- Non-small cell lung cancer (NSCLC) – Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
- Non-small cell lung cancer (NSCLC) – Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation
- Treatment of melanoma, Treatment of solid malignant tumors (excluding melanoma)
- Dabrafenib was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.[rx] Later, it was used in combination with trametinib for the treatment of unresectable or metastatic melanoma with V600E or V600K mutations, either as primary treatment or adjuvant treatment.[rx]
- Metastatic Anaplastic Thyroid Cancer
- Metastatic Melanoma
- Metastatic Non-Small Cell Lung Cancer
- Unresectable Melanoma
- Unresectable or Metastatic Solid Tumors
- Locally advanced Thyroid Cancer, Anaplastic
Use in Cancer
Dabrafenib mesylate is approved to be used alone or with trametinib to treat patients whose cancer has a certain mutation in the BRAF gene, including:
- Anaplastic thyroid cancer is locally advanced or has spread to other parts of the body and cannot be treated with local therapy. It is used with trametinib.
- Melanoma. It is used:
- Trametinib in patients who have had surgery to remove cancer that has spread to the lymph nodes.
- Alone or with trametinib in patients whose cancer cannot be removed by surgery or has spread to other parts of the body.
- Non-small cell lung cancer that has metastasized. It is used with trametinib.
- Solid tumors. It is used with trametinib in adults and children aged 6 years and older whose tumors cannot be removed by surgery or have spread to other parts of the body and have gotten worse after other treatments and cannot be treated with other therapies.¹
This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that dabrafenib mesylate provides a clinical benefit in these patients.
Dabrafenib mesylate is also being studied in the treatment of other types of cancer.
Contraindications
- Dabrafenib is not indicated for the treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC
- squamous cell carcinoma
- diabetes
- inflammation of the iris – the colored part of the eyeball
- inflammation of the uvea of the eye
- chronic heart failure
- abnormal EKG with QT changes from birth
- bleeding
- a body temperature higher than 101 degrees Fahrenheit
- pregnancy
- a patient who is producing milk and breastfeeding
- basal cell carcinoma of the skin
- anemia from pyruvate kinase and G6PD deficiencies
- a type of slow growing skin cancer called a keratoacanthoma
- progression of cancer with the RAS mutation
- Child-Pugh class B liver impairment
- Child-Pugh class C liver impairment
Dosage
Strengths: 75 mg; 50 mg
Non-Small Cell Lung Cancer
- 150 mg orally 2 times a day, either as monotherapy or in combination with trametinib
- Duration of Therapy: Until disease progression or unacceptable toxicity occurs
- Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to treatment initiation with FDA-approved test.
- Take doses approximately 12 hours apart.
- Take this drug at least 1 hour before or 2 hours after a meal.
- Do not take a missed dose within 6 hours of the next dose.
- Do not open, crush, or break capsules.
- As a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an approved test
- In combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an approved test
- In combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an approved test, and involvement of lymph node(s), following complete resection
- In combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an approved test
- In combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
Melanoma – Metastatic
- 150 mg orally 2 times a day, either as monotherapy or in combination with trametinib
Duration of Therapy: Until disease progression or unacceptable toxicity occurs - Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to treatment initiation with FDA-approved test.
- Take doses approximately 12 hours apart.
- Take this drug at least 1 hour before or 2 hours after a meal.
- Do not take a missed dose within 6 hours of the next dose.
- Do not open, crush, or break capsules.
- As a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an approved test
- In combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an approved test
- In combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an approved test, and involvement of lymph node(s), following complete resection
- In combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an approved test
- In combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
Thyroid Cancer
- 150 mg orally 2 times a day, either as monotherapy or in combination with trametinib
Duration of Therapy: Until disease progression or unacceptable toxicity occurs - Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to treatment initiation with FDA-approved test.
- Take doses approximately 12 hours apart.
- Take this drug at least 1 hour before or 2 hours after a meal.
- Do not take a missed dose within 6 hours of the next dose.
- Do not open, crush, or break capsules.
- As a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an approved test
- In combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an approved test
- In combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an approved test, and involvement of lymph node(s), following complete resection
- In combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an approved test
- In combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
For Oral
For oral dosage form (capsules):
For melanoma (skin cancer), non-small cell lung cancer, anaplastic thyroid cancer, and solid tumors:
- Adults—150 milligrams (mg) 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated.
- Children 6 years of age and older—The dose is based on body weight and must be determined by your doctor.
- Weighing 51 kilograms (kg) or more—150 milligrams (mg) 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated.
- Weighing 38 to 50 kg—100 mg 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated.
- Weighing 26 to 37 kg—75 mg 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated.
- Children younger than 6 years of age—Use and dose must be determined by your doctor.
Dose Adjustments
DOSE REDUCTIONS FOR ADVERSE REACTIONS:
- First Dose Reduction: 100 mg twice a day
- Second Dose Reduction: 75 mg twice a day
- Third Dose Reduction: 50 mg twice a day
- Subsequent Modification: Permanently discontinue treatment if unable to tolerate 50 mg twice a day.
For New Primary Cutaneous Malignancies that develop: No dose modifications are recommended.
For New Primary Non-Cutaneous Malignancies: Permanently discontinue in patients who develop RAS mutation-positive non-cutaneous malignancies.
Fever 101.3F to 104F:
- Withhold dabrafenib until the adverse reaction resolves, then resume at the same dose or at a reduced level.
- NEW PRIMARY CUTANEOUS MALIGNANCIES: No adjustment is recommended.
- NEW PRIMARY NON-CUTANEOUS MALIGNANCIES: Permanently discontinue treatment in patients who develop RAS mutation-positive non-cutaneous malignancies.
CARDIAC:
- Symptomatic Congestive Heart Failure; Absolute Decrease in Left Ventricular Ejection Fraction [LVEF] of Greater Than 20% from Baseline that is Below Lower Level of Normal [LLN]): Withhold treatment, then resume at the same dose upon recovery of cardiac function.
PYREXIA:
- Fever of 101.3 to 104 Degrees Fahrenheit: Withhold treatment until fever resolves, then resume at the same or lower dose level.
- Fever Higher Than 104 Degrees Fahrenheit; Fever Complicated by Rigors, Hypotension, Dehydration, or Renal Failure: Withhold treatment until fever resolves, then resume at a lower dose level OR permanently discontinue treatment.
SKIN TOXICITY (Intolerable Grade 2, Grade 3, or Grade 4): Withhold treatment for up to 3 weeks
- If Improved: Resume at a lower dose.
- If Not Improved: Permanently discontinue treatment.
UVEITIS (Severe OR Mild/Moderate that Does Not Respond to Ocular Therapy): Withhold treatment for up to 6 weeks.
- If Improved to Grade 0 to 1: Resume at same or lower dose level.
- If Not Improved: Permanently discontinue treatment.
OTHER ADVERSE REACTIONS:
INTOLERABLE GRADE 2; ANY GRADE 3: Withhold treatment.
- If Improved to Grade 0 to 1: Resume at a lower dose level.
- If Not Improved: Permanently discontinue treatment.
FIRST OCCURRENCE OF ANY GRADE 4: Withhold treatment until improvement to Grade 0 to 1, then resume at a lower dose level OR permanently discontinue treatment.
RECURRENT GRADE 4: Permanently discontinue treatment.
Comments:
- Dose adjustments are NOT recommended for this drug when it is administered in combination with trametinib for the following adverse reactions: retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED), interstitial lung disease (ILD)/pneumonitis, and uncomplicated venous thromboembolism.
- Consult the manufacturer’s product information for trametinib dosing recommendations.
Administration Advice:
- Direct patients to take this drug at least 1 hour before or 2 hours after a meal, and at similar times every day with an interval of approximately 12 hours between doses.
- Instruct patients to swallow drug capsules whole with water, and not to open, crush, chew, or break capsules.
- Warn patients not to mix capsule contents with food or liquids due to the chemical instability of this drug.
- Advise patients not to take a missed dose within 6 hours of the next scheduled dose.
- In the event of a vomited dose, counsel patients not to retake that dose and to resume dosing with the next scheduled dose.
- Consult the manufacturer product information for trametinib dosing recommendations prior to initiation of combination treatment with this drug.
Side Effects
The Most Common
- headache
- joint, muscle, or back pain
- nausea
- diarrhea
- constipation
- loss of appetite
- cough, runny nose, or sore throat
- hair loss
- tiredness
- changes in skin (new wart, skin sore, or red bump that bleeds or does not heal)
- change in size or color of a mole
- rash, red skin, or pimples
- fever
- fainting
- dizziness, lightheadedness, or weakness
- chills
- decreased urination
- swelling of hands, feet, ankles, or lower legs
- frequent urination
- increased thirst
- eye pain
- red or swollen eyelids
- sensitivity to light
- blurred vision or vision changes, including seeing halos (blurred outline around objects) or colored dots
- swelling, pain, redness, or peeling of skin on the palms and soles of the feet
- ongoing pain that begins in the stomach area but may spread to the back
- unusual bleeding or bruising
- bloody or black, tarry stools
- coughing up or vomiting blood or material that looks like coffee grounds
- chest pain
- shortness of breath
- swelling of the hands, feet, ankles or lower legs
- fast, irregular, or pounding heartbeat
- yellowing of the skin and eyes
More common
- Bleeding gums
- bloody, black, or tarry stools
- bloody or cloudy urine
- blurred vision
- coughing up blood
- difficulty in breathing or swallowing
- dizziness
- dry mouth
- fever
- flushed, dry skin
- fruit-like breath odor
- greatly decreased frequency of urination or amount of urine
- headache
- heartburn
- increased hunger
- increased thirst
- increased urination
- indigestion
- lump or growth on the skin
- nausea
- nosebleed
- prolonged bleeding from cuts
- red or black, tarry stools
- red or dark brown urine
- redness, swelling, or pain of the skin
- scaling of the skin on the hands and feet
- skin blisters
- skin rash
- stomach pain or cramps
- sweating
- swelling of the feet or lower legs
- tingling of the hands and feet
- ulceration of the skin
- unable to move
- unexplained weight loss
- unusual tiredness or weakness
- vomiting
- vomiting of material that looks like coffee grounds, severe and continuing
Rare
- Blurred vision or other change in vision
- change in color vision
- difficulty seeing at night
- eye pain
- increased sensitivity of the eyes to sunlight
- redness of the eye
- tearing
- Blistering, peeling, loosening of the skin
- chills
- cough
- diarrhea
- itching
- joint or muscle pain
- red skin lesions, often with a purple center
- sore throat
- sores, ulcers, or white spots in the mouth or on lips
- swollen, painful, or tender lymph glands in the neck, armpit, or groin
- yellow eyes or skin
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Benzodiazepine | The serum concentration of 1,2-Benzodiazepine can be decreased when it is combined with Dabrafenib. |
| Abacavir | The metabolism of Abacavir can be decreased when combined with Dabrafenib. |
| Abametapir | The serum concentration of Dabrafenib can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Dabrafenib can be increased when combined with Abatacept. |
| Abemaciclib | The serum concentration of Abemaciclib can be decreased when it is combined with Dabrafenib. |
| Abiraterone | The serum concentration of Abiraterone can be decreased when it is combined with Dabrafenib. |
| Abrocitinib | The metabolism of Abrocitinib can be increased when combined with Dabrafenib. |
| Acalabrutinib | The serum concentration of Acalabrutinib can be decreased when it is combined with Dabrafenib. |
| Acamprosate | The excretion of Acamprosate can be decreased when combined with Dabrafenib. |
| Acarbose | The therapeutic efficacy of Acarbose can be decreased when used in combination with Dabrafenib. |
| Acenocoumarol | The serum concentration of Acenocoumarol can be decreased when it is combined with Dabrafenib. |
| Acetaminophen | The serum concentration of Acetaminophen can be decreased when it is combined with Dabrafenib. |
| Acetazolamide | The metabolism of Dabrafenib can be decreased when combined with Acetazolamide. |
| Acetohexamide | The serum concentration of Acetohexamide can be decreased when it is combined with Dabrafenib. |
| Acetyl sulfisoxazole | The metabolism of Dabrafenib can be decreased when combined with Acetyl sulfisoxazole. |
| Acetylsalicylic acid | The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Dabrafenib. |
| Acrivastine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Acrivastine. |
| Acyclovir | The excretion of Acyclovir can be decreased when combined with Dabrafenib. |
| Adalimumab | The metabolism of Dabrafenib can be increased when combined with Adalimumab. |
| Adefovir dipivoxil | The excretion of Adefovir dipivoxil can be decreased when combined with Dabrafenib. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Adenosine. |
| Afatinib | The serum concentration of Dabrafenib can be increased when it is combined with Afatinib. |
| Agomelatine | The metabolism of Dabrafenib can be decreased when combined with Agomelatine. |
| Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Dabrafenib. |
| Albendazole | The serum concentration of Albendazole can be decreased when it is combined with Dabrafenib. |
| Albiglutide | The therapeutic efficacy of Albiglutide can be decreased when used in combination with Dabrafenib. |
| Alclometasone | The serum concentration of Alclometasone can be decreased when it is combined with Dabrafenib. |
| Aldesleukin | The metabolism of Dabrafenib can be decreased when combined with Aldesleukin. |
| Alectinib | The metabolism of Alectinib can be increased when combined with Dabrafenib. |
| Alfentanil | The serum concentration of Alfentanil can be decreased when it is combined with Dabrafenib. |
| Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with Dabrafenib. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Dabrafenib. |
| Aliskiren | The serum concentration of Aliskiren can be decreased when it is combined with Dabrafenib. |
| Allopurinol | The excretion of Allopurinol can be decreased when combined with Dabrafenib. |
| Almasilate | Almasilate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Almotriptan | The serum concentration of Almotriptan can be decreased when it is combined with Dabrafenib. |
| Alogliptin | The serum concentration of Alogliptin can be decreased when it is combined with Dabrafenib. |
| Alosetron | The serum concentration of Alosetron can be decreased when it is combined with Dabrafenib. |
| Alpelisib | The serum concentration of Alpelisib can be increased when it is combined with Dabrafenib. |
| Alprazolam | The metabolism of Alprazolam can be decreased when combined with Dabrafenib. |
| Alprostadil | The excretion of Alprostadil can be decreased when combined with Dabrafenib. |
| Aluminium phosphate | Aluminium phosphate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum hydroxide | Aluminum hydroxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Amantadine | The serum concentration of Amantadine can be increased when it is combined with Dabrafenib. |
| Ambrisentan | The serum concentration of Ambrisentan can be decreased when it is combined with Dabrafenib. |
| Ambroxol | The serum concentration of Ambroxol can be decreased when it is combined with Dabrafenib. |
| Amcinonide | The serum concentration of Amcinonide can be decreased when it is combined with Dabrafenib. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Amifampridine. |
| Aminoglutethimide | The metabolism of Dabrafenib can be increased when combined with Aminoglutethimide. |
| Aminohippuric acid | The excretion of Aminohippuric acid can be decreased when combined with Dabrafenib. |
| Aminophenazone | The serum concentration of Aminophenazone can be decreased when it is combined with Dabrafenib. |
| Aminophylline | The serum concentration of Aminophylline can be decreased when it is combined with Dabrafenib. |
| Amiodarone | The serum concentration of Dabrafenib can be increased when it is combined with Amiodarone. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Dabrafenib. |
| Amitriptyline | The serum concentration of Amitriptyline can be decreased when it is combined with Dabrafenib. |
| Amlodipine | The metabolism of Amlodipine can be increased when combined with Dabrafenib. |
| Amobarbital | The metabolism of Dabrafenib can be increased when combined with Amobarbital. |
| Amodiaquine | The serum concentration of Amodiaquine can be decreased when it is combined with Dabrafenib. |
| Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Dabrafenib. |
| Amprenavir | The serum concentration of Dabrafenib can be increased when it is combined with Amprenavir. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Anagrelide. |
| Anakinra | The metabolism of Dabrafenib can be increased when combined with Anakinra. |
| Anastrozole | The serum concentration of Anastrozole can be decreased when it is combined with Dabrafenib. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Antazoline. |
| Antipyrine | The serum concentration of Antipyrine can be decreased when it is combined with Dabrafenib. |
| Apalutamide | The serum concentration of Apalutamide can be increased when it is combined with Dabrafenib. |
| Apixaban | The serum concentration of Apixaban can be decreased when it is combined with Dabrafenib. |
| Apomorphine | The serum concentration of Apomorphine can be decreased when it is combined with Dabrafenib. |
| Apremilast | The serum concentration of Apremilast can be decreased when it is combined with Dabrafenib. |
| Aprepitant | The serum concentration of Aprepitant can be decreased when it is combined with Dabrafenib. |
| Arformoterol | The serum concentration of Arformoterol can be decreased when it is combined with Dabrafenib. |
| Aripiprazole | The serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib. |
| Aripiprazole | The serum concentration of Aripiprazole lauroxil can be decreased when it is combined with Dabrafenib. |
| Armodafinil | The metabolism of Dabrafenib can be increased when combined with Armodafinil. |
| Arsenic trioxide | The serum concentration of Dabrafenib can be increased when it is combined with Arsenic trioxide. |
| Artemether | The serum concentration of Artemether can be decreased when it is combined with Dabrafenib. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Articaine. |
| Asciminib | The serum concentration of Dabrafenib can be increased when it is combined with Asciminib. |
| Asenapine | The serum concentration of Asenapine can be decreased when it is combined with Dabrafenib. |
| Astemizole | The serum concentration of Astemizole can be decreased when it is combined with Dabrafenib. |
| Asunaprevir | The serum concentration of Asunaprevir can be decreased when it is combined with Dabrafenib. |
| Atazanavir | The serum concentration of Dabrafenib can be increased when it is combined with Atazanavir. |
| Atogepant | The serum concentration of Atogepant can be increased when it is combined with Dabrafenib. |
| Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dabrafenib. |
| Atorvastatin | The metabolism of Atorvastatin can be decreased when combined with Dabrafenib. |
| Atovaquone | The serum concentration of Atovaquone can be decreased when it is combined with Dabrafenib. |
| Atropine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Atropine. |
| Avacopan | The serum concentration of Avacopan can be decreased when it is combined with Dabrafenib. |
| Avanafil | The serum concentration of Avanafil can be decreased when it is combined with Dabrafenib. |
| Avapritinib | The serum concentration of Avapritinib can be decreased when it is combined with Dabrafenib. |
| Avatrombopag | The metabolism of Dabrafenib can be increased when combined with Avatrombopag. |
| Avibactam | The excretion of Avibactam can be decreased when combined with Dabrafenib. |
| Axitinib | The serum concentration of Axitinib can be decreased when it is combined with Dabrafenib. |
| Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Dabrafenib. |
| Azelastine | The serum concentration of Azelastine can be decreased when it is combined with Dabrafenib. |
| Azithromycin | The serum concentration of Azithromycin can be decreased when it is combined with Dabrafenib. |
| Baricitinib | The serum concentration of Baricitinib can be increased when it is combined with Dabrafenib. |
| Bazedoxifene | The metabolism of Bazedoxifene can be decreased when combined with Dabrafenib. |
| Beclomethasone dipropionate | The serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Dabrafenib. |
| Bedaquiline | The serum concentration of Bedaquiline can be decreased when it is combined with Dabrafenib. |
| Belantamab | The serum concentration of Dabrafenib can be increased when it is combined with Belantamab mafodotin. |
| Belinostat | The metabolism of Belinostat can be decreased when combined with Dabrafenib. |
| Belumosudil | The serum concentration of Belumosudil can be decreased when it is combined with Dabrafenib. |
| Belzutifan | The serum concentration of Dabrafenib can be decreased when it is combined with Belzutifan. |
| Bempedoic acid | The excretion of Bempedoic acid can be decreased when combined with Dabrafenib. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Dabrafenib. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Dabrafenib. |
| Benzocaine | The serum concentration of Benzocaine can be decreased when it is combined with Dabrafenib. |
| Benzphetamine | The serum concentration of Benzphetamine can be decreased when it is combined with Dabrafenib. |
| Benzyl alcohol | The serum concentration of Benzyl alcohol can be decreased when it is combined with Dabrafenib. |
| Benzylpenicillin | The excretion of Benzylpenicillin can be decreased when combined with Dabrafenib. |
| Bepridil | The serum concentration of Bepridil can be decreased when it is combined with Dabrafenib. |
| Berotralstat | The serum concentration of Berotralstat can be increased when it is combined with Dabrafenib. |
| Betamethasone | The serum concentration of Betamethasone can be decreased when it is combined with Dabrafenib. |
| Betamethasone phosphate | The serum concentration of Betamethasone phosphate can be decreased when it is combined with Dabrafenib. |
| Betrixaban | The serum concentration of Dabrafenib can be increased when it is combined with Betrixaban. |
| Bexarotene | The serum concentration of Bexarotene can be decreased when it is combined with Dabrafenib. |
| Bezafibrate | The serum concentration of Bezafibrate can be decreased when it is combined with Dabrafenib. |
| Bicalutamide | The serum concentration of Bicalutamide can be decreased when it is combined with Dabrafenib. |
| Bictegravir | The serum concentration of Bictegravir can be decreased when it is combined with Dabrafenib. |
| Bifonazole | The metabolism of Dabrafenib can be decreased when combined with Bifonazole. |
| Bilastine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Bilastine. |
| Bimekizumab | The metabolism of Dabrafenib can be increased when combined with Bimekizumab. |
| Binimetinib | The metabolism of Binimetinib can be decreased when combined with Dabrafenib. |
| Bioallethrin | The serum concentration of Bioallethrin can be decreased when it is combined with Dabrafenib. |
| Bismuth subnitrate | Bismuth subnitrate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bisoprolol | The serum concentration of Bisoprolol can be decreased when it is combined with Dabrafenib. |
| Boceprevir | The serum concentration of Dabrafenib can be increased when it is combined with Boceprevir. |
| Bortezomib | The serum concentration of Bortezomib can be decreased when it is combined with Dabrafenib. |
| Bosentan | The serum concentration of Bosentan can be decreased when it is combined with Dabrafenib. |
| Bosutinib | The serum concentration of Bosutinib can be decreased when it is combined with Dabrafenib. |
| Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib. |
| Bretylium | The risk or severity of QTc prolongation can be increased when Bretylium is combined with Dabrafenib. |
| Brexpiprazole | The serum concentration of Brexpiprazole can be decreased when it is combined with Dabrafenib. |
| Brigatinib | The serum concentration of Brigatinib can be decreased when it is combined with Dabrafenib. |
| Brincidofovir | The serum concentration of Brincidofovir can be increased when it is combined with Dabrafenib. |
| Brinzolamide | The serum concentration of Brinzolamide can be decreased when it is combined with Dabrafenib. |
| Brivaracetam | The serum concentration of Brivaracetam can be decreased when it is combined with Dabrafenib. |
| Bromocriptine | The serum concentration of Bromocriptine can be decreased when it is combined with Dabrafenib. |
| Brompheniramine | The serum concentration of Brompheniramine can be decreased when it is combined with Dabrafenib. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Dabrafenib. |
| Budesonide | The serum concentration of Budesonide can be decreased when it is combined with Dabrafenib. |
| Bumetanide | The excretion of Bumetanide can be decreased when combined with Dabrafenib. |
| Bupivacaine | The serum concentration of Bupivacaine can be decreased when it is combined with Dabrafenib. |
| Buprenorphine | The serum concentration of Buprenorphine can be decreased when it is combined with Dabrafenib. |
| Bupropion | The serum concentration of Bupropion can be decreased when it is combined with Dabrafenib. |
| Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Dabrafenib. |
| Buspirone | The serum concentration of Buspirone can be decreased when it is combined with Dabrafenib. |
| Busulfan | The serum concentration of Busulfan can be decreased when it is combined with Dabrafenib. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Butacaine. |
| Butalbital | The metabolism of Dabrafenib can be increased when combined with Butalbital. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Butamben. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Butriptyline. |
| Cabazitaxel | The serum concentration of Cabazitaxel can be decreased when it is combined with Dabrafenib. |
| Cabergoline | The serum concentration of Cabergoline can be decreased when it is combined with Dabrafenib. |
| Cabotegravir | The metabolism of Cabotegravir can be decreased when combined with Dabrafenib. |
| Cabozantinib | The serum concentration of Cabozantinib can be decreased when it is combined with Dabrafenib. |
| Caffeine | Caffeine may decrease the excretion rate of Dabrafenib which could result in a higher serum level. |
| Calcitriol | The serum concentration of Calcitriol can be decreased when it is combined with Dabrafenib. |
| Calcium carbonate | Calcium carbonate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Canagliflozin | The serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib. |
| Canakinumab | The metabolism of Dabrafenib can be increased when combined with Canakinumab. |
| Candesartan cilexetil | The serum concentration of Dabrafenib can be increased when it is combined with Candesartan cilexetil. |
| Candicidin | The metabolism of Dabrafenib can be decreased when combined with Candicidin. |
| Cannabidiol | The serum concentration of Cannabidiol can be decreased when it is combined with Dabrafenib. |
| Capecitabine | The metabolism of Capecitabine can be decreased when combined with Dabrafenib. |
| Capmatinib | The serum concentration of Capmatinib can be decreased when it is combined with Dabrafenib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Capsaicin. |
| Captopril | The excretion of Captopril can be decreased when combined with Dabrafenib. |
| Carbamazepine | The serum concentration of Carbamazepine can be decreased when it is combined with Dabrafenib. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Carbinoxamine. |
| Carfilzomib | The serum concentration of Dabrafenib can be increased when it is combined with Carfilzomib. |
| Cariprazine | The serum concentration of Cariprazine can be decreased when it is combined with Dabrafenib. |
| Carisoprodol | The serum concentration of Carisoprodol can be decreased when it is combined with Dabrafenib. |
| Carvedilol | The serum concentration of Carvedilol can be decreased when it is combined with Dabrafenib. |
| Caspofungin | The excretion of Caspofungin can be decreased when combined with Dabrafenib. |
| Cefaclor | The excretion of Cefaclor can be decreased when combined with Dabrafenib. |
| Cefazolin | The excretion of Cefazolin can be decreased when combined with Dabrafenib. |
| Cefdinir | The excretion of Cefdinir can be decreased when combined with Dabrafenib. |
| Cefotiam | The excretion of Cefotiam can be decreased when combined with Dabrafenib. |
| Cefradine | The metabolism of Dabrafenib can be increased when combined with Cefradine. |
| Ceftibuten | The excretion of Ceftibuten can be decreased when combined with Dabrafenib. |
| Ceftizoxime | The excretion of Ceftizoxime can be decreased when combined with Dabrafenib. |
| Celecoxib | The serum concentration of Celecoxib can be decreased when it is combined with Dabrafenib. |
| Celiprolol | The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Dabrafenib. |
| Cenobamate | The serum concentration of Cenobamate can be decreased when it is combined with Dabrafenib. |
| Cephalexin | The serum concentration of Cephalexin can be decreased when it is combined with Dabrafenib. |
| Ceritinib | The serum concentration of Ceritinib can be decreased when it is combined with Dabrafenib. |
| Cerivastatin | The serum concentration of Cerivastatin can be decreased when it is combined with Dabrafenib. |
| Certolizumab pegol | The metabolism of Dabrafenib can be increased when combined with Certolizumab pegol. |
| Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Dabrafenib. |
| Cevimeline | The serum concentration of Cevimeline can be decreased when it is combined with Dabrafenib. |
| Chenodeoxycholic acid | The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Dabrafenib. |
| Chloramphenicol | The metabolism of Dabrafenib can be decreased when combined with Chloramphenicol. |
| Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Chlorcyclizine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Chloroprocaine. |
| Chloroquine | The serum concentration of Chloroquine can be decreased when it is combined with Dabrafenib. |
| Chlorpheniramine | The serum concentration of Chlorpheniramine can be decreased when it is combined with Dabrafenib. |
| Chlorpromazine | The serum concentration of Chlorpromazine can be decreased when it is combined with Dabrafenib. |
| Chlorpropamide | The serum concentration of Chlorpropamide can be decreased when it is combined with Dabrafenib. |
| Chlorprothixene | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Dabrafenib. |
| Chlorzoxazone | The serum concentration of Chlorzoxazone can be decreased when it is combined with Dabrafenib. |
| Cholecalciferol | The serum concentration of Cholecalciferol can be decreased when it is combined with Dabrafenib. |
| Cholecystokinin | The excretion of Cholecystokinin can be decreased when combined with Dabrafenib. |
| Cholesterol | Cholesterol may increase the excretion rate of Dabrafenib which could result in a lower serum level and potentially a reduction in efficacy. |
| Cholic Acid | The excretion of Cholic Acid can be decreased when combined with Dabrafenib. |
| Choline | The serum concentration of Choline can be increased when it is combined with Dabrafenib. |
| Choline salicylate | The serum concentration of Choline salicylate can be increased when it is combined with Dabrafenib. |
| Ciclesonide | The serum concentration of Ciclesonide can be decreased when it is combined with Dabrafenib. |
| Cidofovir | The excretion of Cidofovir can be decreased when combined with Dabrafenib. |
| Cilostazol | The serum concentration of Cilostazol can be increased when it is combined with Dabrafenib. |
| Cimetidine | Cimetidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cinacalcet | The serum concentration of Cinacalcet can be decreased when it is combined with Dabrafenib. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Cinchocaine. |
| Cinnarizine | The serum concentration of Cinnarizine can be decreased when it is combined with Dabrafenib. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Cinoxacin. |
| Ciprofloxacin | The metabolism of Dabrafenib can be decreased when combined with Ciprofloxacin. |
| Cisapride | The serum concentration of Cisapride can be decreased when it is combined with Dabrafenib. |
| Cisplatin | The serum concentration of Cisplatin can be increased when it is combined with Dabrafenib. |
| Citalopram | The serum concentration of Citalopram can be decreased when it is combined with Dabrafenib. |
| Cladribine | Dabrafenib may decrease the excretion rate of Cladribine which could result in a higher serum level. |
| Clarithromycin | The serum concentration of Dabrafenib can be increased when it is combined with Clarithromycin. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Clemastine. |
| Clevidipine | The serum concentration of Clevidipine can be decreased when it is combined with Dabrafenib. |
| Clindamycin | The metabolism of Clindamycin can be increased when combined with Dabrafenib. |
| Clobazam | The serum concentration of Clobazam can be decreased when it is combined with Dabrafenib. |
| Clobetasol | The serum concentration of Clobetasol can be decreased when it is combined with Dabrafenib. |
| Clobetasol propionate | The serum concentration of Clobetasol propionate can be decreased when it is combined with Dabrafenib. |
| Clobetasone | The serum concentration of Clobetasone can be decreased when it is combined with Dabrafenib. |
| Clofarabine | The serum concentration of Clofarabine can be increased when it is combined with Dabrafenib. |
| Clofazimine | The serum concentration of Dabrafenib can be increased when it is combined with Clofazimine. |
| Clofibrate | The serum concentration of Clofibrate can be decreased when it is combined with Dabrafenib. |
| Clomifene | The serum concentration of Dabrafenib can be increased when it is combined with Clomifene. |
| Clomipramine | The serum concentration of Clomipramine can be decreased when it is combined with Dabrafenib. |
| Clonazepam | The metabolism of Clonazepam can be increased when combined with Dabrafenib. |
| Clonidine | The serum concentration of Clonidine can be decreased when it is combined with Dabrafenib. |
| Clopidogrel | The serum concentration of Clopidogrel can be decreased when it is combined with Dabrafenib. |
| Clorazepic acid | The serum concentration of Clorazepic acid can be decreased when it is combined with Dabrafenib. |
| Clotiazepam | The serum concentration of Clotiazepam can be decreased when it is combined with Dabrafenib. |
| Clozapine | The serum concentration of Clozapine can be decreased when it is combined with Dabrafenib. |
| Cobicistat | The serum concentration of Dabrafenib can be increased when it is combined with Cobicistat. |
| Cobimetinib | The serum concentration of Cobimetinib can be decreased when it is combined with Dabrafenib. |
| Cocaine | The serum concentration of Cocaine can be decreased when it is combined with Dabrafenib. |
| Codeine | The serum concentration of Codeine can be decreased when it is combined with Dabrafenib. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with Dabrafenib. |
| Conivaptan | The serum concentration of Dabrafenib can be increased when it is combined with Conivaptan. |
| Conjugated estrogens | The serum concentration of Conjugated estrogens can be decreased when it is combined with Dabrafenib. |
| Copanlisib | The serum concentration of Copanlisib can be decreased when it is combined with Dabrafenib. |
| Corticotropin | The serum concentration of Corticotropin can be decreased when it is combined with Dabrafenib. |
| Cortisone acetate | The serum concentration of Cortisone acetate can be decreased when it is combined with Dabrafenib. |
| Crizotinib | The metabolism of Dabrafenib can be decreased when combined with Crizotinib. |
| Curcumin | The serum concentration of Dabrafenib can be increased when it is combined with Curcumin. |
| Cyclandelate | The serum concentration of Cyclandelate can be decreased when it is combined with Dabrafenib. |
| Cyclizine | The metabolism of Dabrafenib can be decreased when combined with Cyclizine. |
| Cyclobenzaprine | The serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib. |
| Cyclophosphamide | The serum concentration of Cyclophosphamide can be decreased when it is combined with Dabrafenib. |
| Cyclosporine | The serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib. |
| Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Dabrafenib. |
| Cyproterone acetate | The serum concentration of Cyproterone acetate can be decreased when it is combined with Dabrafenib. |
| Dabigatran etexilate | The serum concentration of Dabrafenib can be increased when it is combined with Dabigatran etexilate. |
| Daclatasvir | The serum concentration of Daclatasvir can be decreased when it is combined with Dabrafenib. |
| Dacomitinib | The serum concentration of Dacomitinib can be decreased when it is combined with Dabrafenib. |
| Dactinomycin | Dabrafenib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. |
| Dalfampridine | The serum concentration of Dalfampridine can be increased when it is combined with Dabrafenib. |
| Dalfopristin | The metabolism of Dabrafenib can be decreased when combined with Dalfopristin. |
| Danazol | The serum concentration of Dabrafenib can be increased when it is combined with Danazol. |
| Dapagliflozin | The serum concentration of Dapagliflozin can be decreased when it is combined with Dabrafenib. |
| Dapsone | The serum concentration of Dapsone can be decreased when it is combined with Dabrafenib. |
| Daptomycin | The serum concentration of Dabrafenib can be increased when it is combined with Daptomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dabrafenib. |
| Daridorexant | The serum concentration of Daridorexant can be decreased when it is combined with Dabrafenib. |
| Darifenacin | The serum concentration of Darifenacin can be decreased when it is combined with Dabrafenib. |
| Darolutamide | The serum concentration of Dabrafenib can be increased when it is combined with Darolutamide. |
| Darunavir | The serum concentration of Dabrafenib can be increased when it is combined with Darunavir. |
| Dasabuvir | The serum concentration of Dasabuvir can be decreased when it is combined with Dabrafenib. |
| Dasatinib | The serum concentration of Dasatinib can be decreased when it is combined with Dabrafenib. |
| Daunorubicin | The metabolism of Dabrafenib can be decreased when combined with Daunorubicin. |
| Deferasirox | The metabolism of Dabrafenib can be increased when combined with Deferasirox. |
| Deflazacort | The serum concentration of Deflazacort can be decreased when it is combined with Dabrafenib. |
| Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dabrafenib. |
| Delafloxacin | The metabolism of Dabrafenib can be increased when combined with Delafloxacin. |
| Delamanid | The serum concentration of Delamanid can be decreased when it is combined with Dabrafenib. |
| Delavirdine | The serum concentration of Dabrafenib can be increased when it is combined with Delavirdine. |
| Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Dabrafenib. |
| Desipramine | The metabolism of Dabrafenib can be decreased when combined with Desipramine. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Desloratadine. |
| Desogestrel | The serum concentration of Desogestrel can be decreased when it is combined with Dabrafenib. |
| Desonide | The serum concentration of Desonide can be decreased when it is combined with Dabrafenib. |
| Desoxycorticosterone | The serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Dabrafenib. |
| Desvenlafaxine | The serum concentration of Desvenlafaxine can be decreased when it is combined with Dabrafenib. |
| Deutetrabenazine | The serum concentration of Deutetrabenazine can be decreased when it is combined with Dabrafenib. |
| Dexamethasone | The serum concentration of Dexamethasone can be decreased when it is combined with Dabrafenib. |
| Dexamethasone | The serum concentration of Dexamethasone acetate can be decreased when it is combined with Dabrafenib. |
| Dexbrompheniramine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dabrafenib. |
| Dexchlorpheniramine | The serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Dabrafenib. |
| Dexibuprofen | The serum concentration of Dexibuprofen can be decreased when it is combined with Dabrafenib. |
| Dexlansoprazole | The serum concentration of Dexlansoprazole can be decreased when it is combined with Dabrafenib. |
| Dextromethorphan | The serum concentration of Dextromethorphan can be decreased when it is combined with Dabrafenib. |
| Dextropropoxyphene | The serum concentration of Dextropropoxyphene can be decreased when it is combined with Dabrafenib. |
| Diacerein | The metabolism of Dabrafenib can be decreased when combined with Diacerein. |
| Diazepam | The serum concentration of Diazepam can be decreased when it is combined with Dabrafenib. |
| Diclofenac | The serum concentration of Diclofenac can be decreased when it is combined with Dabrafenib. |
| Dicloxacillin | The metabolism of Dabrafenib can be increased when combined with Dicloxacillin. |
| Dicoumarol | The serum concentration of Dicoumarol can be decreased when it is combined with Dabrafenib. |
| Didanosine | The excretion of Didanosine can be decreased when combined with Dabrafenib. |
| Dienogest | The serum concentration of Dienogest can be decreased when it is combined with Dabrafenib. |
| Diethylstilbestrol | The serum concentration of Diethylstilbestrol can be decreased when it is combined with Dabrafenib. |
| Difluocortolone | The serum concentration of Difluocortolone can be decreased when it is combined with Dabrafenib. |
| Difluprednate | The serum concentration of Difluprednate can be decreased when it is combined with Dabrafenib. |
| Digitoxin | The serum concentration of Digitoxin can be decreased when it is combined with Dabrafenib. |
| Digoxin | The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dabrafenib. |
| Dihydro-alpha | The serum concentration of Dihydro-alpha-ergocryptine can be decreased when it is combined with Dabrafenib. |
| Dihydrocodeine | The serum concentration of Dihydrocodeine can be decreased when it is combined with Dabrafenib. |
| Dihydroergocornine | The serum concentration of Dihydroergocornine can be decreased when it is combined with Dabrafenib. |
| Dihydroergocristine | The serum concentration of Dihydroergocristine can be decreased when it is combined with Dabrafenib. |
| Dihydroergotamine | The serum concentration of Dihydroergotamine can be decreased when it is combined with Dabrafenib. |
| Diltiazem | The serum concentration of Diltiazem can be decreased when it is combined with Dabrafenib. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Dimenhydrinate. |
| Dimethyl sulfoxide | The metabolism of Dabrafenib can be decreased when combined with Dimethyl sulfoxide. |
| Dinoprostone | The excretion of Dinoprostone can be decreased when combined with Dabrafenib. |
| Diosmin | The serum concentration of Dabrafenib can be increased when it is combined with Diosmin. |
| Diphenhydramine | The serum concentration of Diphenhydramine can be decreased when it is combined with Dabrafenib. |
| Disopyramide | The serum concentration of Disopyramide can be decreased when it is combined with Dabrafenib. |
| Disulfiram | The serum concentration of Disulfiram can be decreased when it is combined with Dabrafenib. |
| Docetaxel | The serum concentration of Docetaxel can be decreased when it is combined with Dabrafenib. |
| Doconexent | The serum concentration of Doconexent can be decreased when it is combined with Dabrafenib. |
| Dofetilide | The serum concentration of Dofetilide can be decreased when it is combined with Dabrafenib. |
| Dolasetron | The serum concentration of Dolasetron can be decreased when it is combined with Dabrafenib. |
| Dolutegravir | Dabrafenib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. |
| Domperidone | The serum concentration of Domperidone can be decreased when it is combined with Dabrafenib. |
| Donepezil | The serum concentration of Donepezil can be decreased when it is combined with Dabrafenib. |
| Dopamine | The serum concentration of Dopamine can be increased when it is combined with Dabrafenib. |
| Doravirine | The serum concentration of Doravirine can be decreased when it is combined with Dabrafenib. |
| Doripenem | The excretion of Doripenem can be decreased when combined with Dabrafenib. |
| Dosulepin | The serum concentration of Dosulepin can be decreased when it is combined with Dabrafenib. |
| Doxazosin | The serum concentration of Doxazosin can be decreased when it is combined with Dabrafenib. |
| Doxepin | The serum concentration of Doxepin can be decreased when it is combined with Dabrafenib. |
| Doxorubicin | The serum concentration of Doxorubicin can be decreased when it is combined with Dabrafenib. |
| Doxylamine | The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Dabrafenib. |
| Dronabinol | The serum concentration of Dronabinol can be decreased when it is combined with Dabrafenib. |
| Dronedarone | The serum concentration of Dabrafenib can be increased when it is combined with Dronedarone. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Droperidol. |
| Drospirenone | The serum concentration of Drospirenone can be decreased when it is combined with Dabrafenib. |
| Dulaglutide | The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dabrafenib. |
| Duloxetine | The serum concentration of Duloxetine can be decreased when it is combined with Dabrafenib. |
| Duvelisib | The serum concentration of Duvelisib can be decreased when it is combined with Dabrafenib. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Dyclonine. |
| Dydrogesterone | The serum concentration of Dydrogesterone can be decreased when it is combined with Dabrafenib. |
| Ebastine | The serum concentration of Ebastine can be decreased when it is combined with Dabrafenib. |
| Echinacea | The metabolism of Dabrafenib can be increased when combined with Echinacea. |
| Econazole | The serum concentration of Dabrafenib can be increased when it is combined with Econazole. |
| Edoxaban | The serum concentration of Dabrafenib can be increased when it is combined with Edoxaban. |
| Efavirenz | The serum concentration of Dabrafenib can be increased when it is combined with Efavirenz. |
| Elagolix | The serum concentration of Elagolix can be decreased when it is combined with Dabrafenib. |
| Elbasvir | The serum concentration of Elbasvir can be decreased when it is combined with Dabrafenib. |
| Eletriptan | The serum concentration of Eletriptan can be decreased when it is combined with Dabrafenib. |
| Elexacaftor | The serum concentration of Elexacaftor can be decreased when it is combined with Dabrafenib. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Dabrafenib. |
| Eltrombopag | The serum concentration of Eltrombopag can be decreased when it is combined with Dabrafenib. |
| Eluxadoline | The serum concentration of Eluxadoline can be increased when it is combined with Dabrafenib. |
| Elvitegravir | The serum concentration of Dabrafenib can be increased when it is combined with Elvitegravir. |
| Emapalumab | The metabolism of Dabrafenib can be increased when combined with Emapalumab. |
| Emedastine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Emedastine. |
| Empagliflozin | The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib. |
| Enalapril | The excretion of Enalapril can be decreased when combined with Dabrafenib. |
| Enasidenib | The serum concentration of Enasidenib can be decreased when it is combined with Dabrafenib. |
| Encainide | The risk or severity of QTc prolongation can be increased when Encainide is combined with Dabrafenib. |
| Encorafenib | The serum concentration of Encorafenib can be decreased when it is combined with Dabrafenib. |
| Enfortumab vedotin | The serum concentration of Enfortumab vedotin can be decreased when it is combined with Dabrafenib. |
| Enoxacin | The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Dabrafenib. |
| Entrectinib | The metabolism of Entrectinib can be increased when combined with Dabrafenib. |
| Enzalutamide | The serum concentration of Enzalutamide can be increased when it is combined with Dabrafenib. |
| Epinastine | The serum concentration of Epinastine can be decreased when it is combined with Dabrafenib. |
| Epinephrine | The metabolism of Dabrafenib can be decreased when combined with Epinephrine. |
| Eplerenone | The serum concentration of Eplerenone can be decreased when it is combined with Dabrafenib. |
| Eravacycline | The serum concentration of Eravacycline can be decreased when it is combined with Dabrafenib. |
| Erdafitinib | The metabolism of Erdafitinib can be increased when combined with Dabrafenib. |
| Ergoloid mesylate | The serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib. |
| Ergometrine | The serum concentration of Ergometrine can be decreased when it is combined with Dabrafenib. |
| Ergotamine | The serum concentration of Dabrafenib can be increased when it is combined with Ergotamine. |
| Eribulin | The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dabrafenib. |
| Erlotinib | The serum concentration of Erlotinib can be decreased when it is combined with Dabrafenib. |
| Ertugliflozin | The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Dabrafenib. |
| Erythromycin | The serum concentration of Erythromycin can be decreased when it is combined with Dabrafenib. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dabrafenib. |
| Escitalopram | The serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib. |
| Esketamine | The serum concentration of Esketamine can be decreased when it is combined with Dabrafenib. |
| Eslicarbazepine | The metabolism of Dabrafenib can be increased when combined with Eslicarbazepine. |
| Eslicarbazepine | The metabolism of Dabrafenib can be increased when combined with Eslicarbazepine acetate. |
| Esmolol | The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dabrafenib. |
| Esomeprazole | The serum concentration of Esomeprazole can be decreased when it is combined with Dabrafenib. |
| Estazolam | The serum concentration of Estazolam can be decreased when it is combined with Dabrafenib. |
| Esterified estrogens | The serum concentration of Esterified estrogens can be decreased when it is combined with Dabrafenib. |
| Estetrol | The serum concentration of Estetrol can be decreased when it is combined with Dabrafenib. |
| Estradiol | The serum concentration of Estradiol can be decreased when it is combined with Dabrafenib. |
| Estradiol acetate | The serum concentration of Estradiol acetate can be decreased when it is combined with Dabrafenib. |
| Estradiol benzoate | The serum concentration of Estradiol benzoate can be decreased when it is combined with Dabrafenib. |
| Estradiol cypionate | The serum concentration of Estradiol cypionate can be decreased when it is combined with Dabrafenib. |
| Estradiol dienanthate | The serum concentration of Estradiol dienanthate can be decreased when it is combined with Dabrafenib. |
| Estradiol valerate | The serum concentration of Estradiol valerate can be decreased when it is combined with Dabrafenib. |
| Estramustine | The serum concentration of Estramustine can be decreased when it is combined with Dabrafenib. |
| Estrone | The serum concentration of Estrone can be decreased when it is combined with Dabrafenib. |
| Estrone sulfate | The serum concentration of Estrone sulfate can be decreased when it is combined with Dabrafenib. |
| Eszopiclone | The serum concentration of Eszopiclone can be decreased when it is combined with Dabrafenib. |
| Etanercept | The metabolism of Dabrafenib can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Dabrafenib can be decreased when combined with Ethambutol. |
| Ethanol | The serum concentration of Ethanol can be decreased when it is combined with Dabrafenib. |
| Ethinylestradiol | The serum concentration of Ethinylestradiol can be decreased when it is combined with Dabrafenib. |
| Ethosuximide | The serum concentration of Ethosuximide can be decreased when it is combined with Dabrafenib. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Ethyl chloride. |
| Ethynodiol | The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Dabrafenib. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Etidocaine. |
| Etodolac | The serum concentration of Etodolac can be decreased when it is combined with Dabrafenib. |
| Etonogestrel | The serum concentration of Etonogestrel can be decreased when it is combined with Dabrafenib. |
| Etoposide | The serum concentration of Etoposide can be decreased when it is combined with Dabrafenib. |
| Etoricoxib | The serum concentration of Etoricoxib can be decreased when it is combined with Dabrafenib. |
| Etravirine | The serum concentration of Etravirine can be decreased when it is combined with Dabrafenib. |
| Everolimus | The serum concentration of Everolimus can be decreased when it is combined with Dabrafenib. |
| Exemestane | The serum concentration of Exemestane can be decreased when it is combined with Dabrafenib. |
| Exenatide | The therapeutic efficacy of Exenatide can be decreased when used in combination with Dabrafenib. |
| Ezetimibe | Dabrafenib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. |
| Ezogabine | The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Dabrafenib. |
| Famotidine | Famotidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Favipiravir | The serum concentration of Dabrafenib can be increased when it is combined with Favipiravir. |
| Febuxostat | The excretion of Dabrafenib can be decreased when combined with Febuxostat. |
| Fedratinib | The serum concentration of Fedratinib can be decreased when it is combined with Dabrafenib. |
| Felbamate | The serum concentration of Felbamate can be decreased when it is combined with Dabrafenib. |
| Felodipine | The serum concentration of Dabrafenib can be increased when it is combined with Felodipine. |
| Fenfluramine | The serum concentration of Fenfluramine can be decreased when it is combined with Dabrafenib. |
| Fenofibrate | The serum concentration of Fenofibrate can be decreased when it is combined with Dabrafenib. |
| Fentanyl | The metabolism of Fentanyl can be decreased when combined with Dabrafenib. |
| Fesoterodine | The serum concentration of Fesoterodine can be decreased when it is combined with Dabrafenib. |
| Fexinidazole | The serum concentration of Fexinidazole can be decreased when it is combined with Dabrafenib. |
| Fexofenadine | The excretion of Fexofenadine can be decreased when combined with Dabrafenib. |
| Filgotinib | The serum concentration of Dabrafenib can be increased when it is combined with Filgotinib. |
| Finasteride | The serum concentration of Finasteride can be decreased when it is combined with Dabrafenib. |
| Finerenone | The serum concentration of Finerenone can be increased when it is combined with Dabrafenib. |
| Fish oil | The serum concentration of Fish oil can be decreased when it is combined with Dabrafenib. |
| Flecainide | The metabolism of Dabrafenib can be decreased when combined with Flecainide. |
| Flibanserin | The serum concentration of Flibanserin can be decreased when it is combined with Dabrafenib. |
| Floxuridine | The metabolism of Dabrafenib can be decreased when combined with Floxuridine. |
| Flucloxacillin | The metabolism of Dabrafenib can be increased when combined with Flucloxacillin. |
| Fluconazole | The serum concentration of Dabrafenib can be increased when it is combined with Fluconazole. |
| Fludrocortisone | The serum concentration of Fludrocortisone can be decreased when it is combined with Dabrafenib. |
| Fluindione | The serum concentration of Fluindione can be decreased when it is combined with Dabrafenib. |
| Flumethasone | The serum concentration of Flumethasone can be decreased when it is combined with Dabrafenib. |
| Flunarizine | The serum concentration of Flunarizine can be decreased when it is combined with Dabrafenib. |
| Flunisolide | The serum concentration of Flunisolide can be decreased when it is combined with Dabrafenib. |
| Flunitrazepam | The serum concentration of Flunitrazepam can be decreased when it is combined with Dabrafenib. |
| Fluocinolone acetonide | The serum concentration of Fluocinolone acetonide can be decreased when it is combined with Dabrafenib. |
| Fluocinonide | The serum concentration of Fluocinonide can be decreased when it is combined with Dabrafenib. |
| Fluocortolone | The serum concentration of Fluocortolone can be decreased when it is combined with Dabrafenib. |
| Fluorescein | The excretion of Fluorescein can be decreased when combined with Dabrafenib. |
| Fluorometholone | The serum concentration of Fluorometholone can be decreased when it is combined with Dabrafenib. |
| Fluorouracil | The serum concentration of Fluorouracil can be decreased when it is combined with Dabrafenib. |
| Fluoxetine | The serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib. |
| Flupentixol | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Flupentixol. |
| Fluprednisolone | The serum concentration of Fluprednisolone can be decreased when it is combined with Dabrafenib. |
| Flurandrenolide | The serum concentration of Flurandrenolide can be decreased when it is combined with Dabrafenib. |
| Flurazepam | The serum concentration of Flurazepam can be decreased when it is combined with Dabrafenib. |
| Flurbiprofen | The serum concentration of Flurbiprofen can be decreased when it is combined with Dabrafenib. |
| Fluspirilene | The serum concentration of Fluspirilene can be decreased when it is combined with Dabrafenib. |
| Flutamide | The serum concentration of Flutamide can be decreased when it is combined with Dabrafenib. |
| Fluticasone | The serum concentration of Dabrafenib can be increased when it is combined with Fluticasone. |
| Fluticasone furoate | The serum concentration of Dabrafenib can be increased when it is combined with Fluticasone furoate. |
| Fluticasone propionate | The serum concentration of Dabrafenib can be increased when it is combined with Fluticasone propionate. |
| Fluvastatin | The serum concentration of Fluvastatin can be decreased when it is combined with Dabrafenib. |
| Fluvoxamine | The serum concentration of Fluvoxamine can be decreased when it is combined with Dabrafenib. |
| Folic acid | Dabrafenib may decrease the excretion rate of Folic acid which could result in a higher serum level. |
| Formestane | The metabolism of Dabrafenib can be increased when combined with Formestane. |
| Formoterol | The serum concentration of Formoterol can be decreased when it is combined with Dabrafenib. |
| Fosamprenavir | The serum concentration of Fosamprenavir can be decreased when it is combined with Dabrafenib. |
| Fosaprepitant | The serum concentration of Fosaprepitant can be decreased when it is combined with Dabrafenib. |
| Foscarnet | The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dabrafenib. |
| Fosnetupitant | The serum concentration of Fosnetupitant can be decreased when it is combined with Dabrafenib. |
| Fosphenytoin | The serum concentration of Fosphenytoin can be decreased when it is combined with Dabrafenib. |
| Fostamatinib | The serum concentration of Fostamatinib can be decreased when it is combined with Dabrafenib. |
| Fostemsavir | The serum concentration of Fostemsavir can be decreased when it is combined with Dabrafenib. |
| Fulvestrant | The metabolism of Fulvestrant can be decreased when combined with Dabrafenib. |
| Furosemide | The metabolism of Furosemide can be decreased when combined with Dabrafenib. |
| Fusidic acid | The serum concentration of Fusidic acid can be decreased when it is combined with Dabrafenib. |
| Futibatinib | The serum concentration of Futibatinib can be decreased when it is combined with Dabrafenib. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Gadobenic acid. |
| Gadoxetic acid | The excretion of Gadoxetic acid can be decreased when combined with Dabrafenib. |
| Galantamine | The serum concentration of Galantamine can be decreased when it is combined with Dabrafenib. |
| Gatifloxacin | The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Dabrafenib. |
| Gefitinib | The serum concentration of Gefitinib can be decreased when it is combined with Dabrafenib. |
| Gemcitabine | The serum concentration of Dabrafenib can be increased when it is combined with Gemcitabine. |
| Gemfibrozil | The serum concentration of Dabrafenib can be increased when it is combined with Gemfibrozil. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Gemifloxacin. |
| Gentamicin | The serum concentration of Gentamicin can be increased when it is combined with Dabrafenib. |
| Gestrinone | The serum concentration of Gestrinone can be decreased when it is combined with Dabrafenib. |
| Gilteritinib | The serum concentration of Gilteritinib can be decreased when it is combined with Dabrafenib. |
| Ginkgo biloba | The metabolism of Dabrafenib can be decreased when combined with Ginkgo biloba. |
| Glasdegib | The serum concentration of Glasdegib can be decreased when it is combined with Dabrafenib. |
| Glecaprevir | The serum concentration of Dabrafenib can be increased when it is combined with Glecaprevir. |
| Gliclazide | The serum concentration of Gliclazide can be decreased when it is combined with Dabrafenib. |
| Glimepiride | The serum concentration of Glimepiride can be decreased when it is combined with Dabrafenib. |
| Glipizide | The serum concentration of Glipizide can be decreased when it is combined with Dabrafenib. |
| Gliquidone | The serum concentration of Gliquidone can be decreased when it is combined with Dabrafenib. |
| Glyburide | The serum concentration of Glyburide can be decreased when it is combined with Dabrafenib. |
| Glycerol phenylbutyrate | The metabolism of Dabrafenib can be increased when combined with Glycerol phenylbutyrate. |
| Glymidine | The therapeutic efficacy of Glymidine can be decreased when used in combination with Dabrafenib. |
| Golimumab | The metabolism of Dabrafenib can be increased when combined with Golimumab. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Goserelin. |
| Granisetron | The serum concentration of Granisetron can be decreased when it is combined with Dabrafenib. |
| Grazoprevir | The serum concentration of Grazoprevir can be decreased when it is combined with Dabrafenib. |
| Grepafloxacin | The serum concentration of Grepafloxacin can be decreased when it is combined with Dabrafenib. |
| Griseofulvin | The metabolism of Dabrafenib can be increased when combined with Griseofulvin. |
| Guanfacine | The serum concentration of Guanfacine can be decreased when it is combined with Dabrafenib. |
| Halcinonide | The serum concentration of Halcinonide can be decreased when it is combined with Dabrafenib. |
| Halofantrine | The serum concentration of Halofantrine can be decreased when it is combined with Dabrafenib. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Haloperidol. |
| Halothane | The serum concentration of Halothane can be decreased when it is combined with Dabrafenib. |
| Histamine | The serum concentration of Histamine can be increased when it is combined with Dabrafenib. |
| Histrelin | The risk or severity of QTc prolongation can be increased when Histrelin is combined with Dabrafenib. |
| Hydralazine | The metabolism of Dabrafenib can be decreased when combined with Hydralazine. |
| Hydrochlorothiazide | The excretion of Hydrochlorothiazide can be decreased when combined with Dabrafenib. |
| Hydrocodone | The serum concentration of Hydrocodone can be decreased when it is combined with Dabrafenib. |
| Hydrocortamate | The metabolism of Dabrafenib can be increased when combined with Hydrocortamate. |
| Hydrocortisone | The serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib. |
| Hydrocortisone acetate | The serum concentration of Hydrocortisone acetate can be decreased when it is combined with Dabrafenib. |
| Hydrocortisone | The serum concentration of Hydrocortisone butyrate can be decreased when it is combined with Dabrafenib. |
| Hydrocortisone | The serum concentration of Hydrocortisone cypionate can be decreased when it is combined with Dabrafenib. |
| Hydrocortisone | The serum concentration of Hydrocortisone phosphate can be decreased when it is combined with Dabrafenib. |
| Hydrocortisone | The serum concentration of Hydrocortisone probutate can be decreased when it is combined with Dabrafenib. |
| Hydrocortisone | The serum concentration of Hydrocortisone succinate can be decreased when it is combined with Dabrafenib. |
| Hydrocortisone | The serum concentration of Hydrocortisone valerate can be decreased when it is combined with Dabrafenib. |
| Hydromorphone | The serum concentration of Hydromorphone can be decreased when it is combined with Dabrafenib. |
| Hydrotalcite | Hydrotalcite can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hydroxychloroquine | The serum concentration of Hydroxychloroquine can be decreased when it is combined with Dabrafenib. |
| Hydroxyprogesterone | The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Dabrafenib. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Hydroxyzine. |
| Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Dabrafenib. |
| Ibandronate | The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dabrafenib. |
| Ibrexafungerp | The serum concentration of Ibrexafungerp can be decreased when it is combined with Dabrafenib. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Dabrafenib. |
| Ibuprofen | The serum concentration of Ibuprofen can be decreased when it is combined with Dabrafenib. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ibutilide. |
| Idarubicin | The serum concentration of Idarubicin can be decreased when it is combined with Dabrafenib. |
| Idelalisib | The serum concentration of Idelalisib can be decreased when it is combined with Dabrafenib. |
| Ifosfamide | The metabolism of Ifosfamide can be increased when combined with Dabrafenib. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with Dabrafenib. |
| Imatinib | The serum concentration of Imatinib can be decreased when it is combined with Dabrafenib. |
| Imipramine | The serum concentration of Imipramine can be decreased when it is combined with Dabrafenib. |
| Imiquimod | The serum concentration of Imiquimod can be decreased when it is combined with Dabrafenib. |
| Indacaterol | The serum concentration of Indacaterol can be decreased when it is combined with Dabrafenib. |
| Indapamide | The serum concentration of Indapamide can be decreased when it is combined with Dabrafenib. |
| Indinavir | The serum concentration of Dabrafenib can be increased when it is combined with Indinavir. |
| Indomethacin | The serum concentration of Indomethacin can be decreased when it is combined with Dabrafenib. |
| Infigratinib | The serum concentration of Infigratinib can be decreased when it is combined with Dabrafenib. |
| Infliximab | The metabolism of Dabrafenib can be increased when combined with Infliximab. |
| Inotersen | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Inotersen. |
| Inotuzumab | The serum concentration of Dabrafenib can be increased when it is combined with Inotuzumab ozogamicin. |
| Insulin aspart | The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Dabrafenib. |
| Insulin beef | The therapeutic efficacy of Insulin beef can be decreased when used in combination with Dabrafenib. |
| Insulin degludec | The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Dabrafenib. |
| Insulin detemir | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Dabrafenib. |
| Insulin glargine | The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Dabrafenib. |
| Insulin glulisine | The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Dabrafenib. |
| Insulin human | The therapeutic efficacy of Insulin human can be decreased when used in combination with Dabrafenib. |
| Insulin lispro | The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Dabrafenib. |
| Insulin pork | The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dabrafenib. |
| Ipecac | The serum concentration of Ipecac can be decreased when it is combined with Dabrafenib. |
| Irbesartan | The serum concentration of Irbesartan can be decreased when it is combined with Dabrafenib. |
| Irinotecan | The risk or severity of neutropenia can be increased when Dabrafenib is combined with Irinotecan. |
| Isavuconazole | The serum concentration of Isavuconazole can be decreased when it is combined with Dabrafenib. |
| Isavuconazonium | The serum concentration of Isavuconazonium can be decreased when it is combined with Dabrafenib. |
| Isoflurane | The serum concentration of Isoflurane can be decreased when it is combined with Dabrafenib. |
| Isoniazid | The metabolism of Dabrafenib can be decreased when combined with Isoniazid. |
| Isotretinoin | The serum concentration of Isotretinoin can be decreased when it is combined with Dabrafenib. |
| Isradipine | The serum concentration of Isradipine can be decreased when it is combined with Dabrafenib. |
| Istradefylline | The serum concentration of Istradefylline can be decreased when it is combined with Dabrafenib. |
| Itraconazole | The serum concentration of Dabrafenib can be increased when it is combined with Itraconazole. |
| Ivabradine | The serum concentration of Ivabradine can be decreased when it is combined with Dabrafenib. |
| Ivacaftor | The serum concentration of Ivacaftor can be decreased when it is combined with Dabrafenib. |
| Ivermectin | The serum concentration of Ivermectin can be decreased when it is combined with Dabrafenib. |
| Ivosidenib | The metabolism of Dabrafenib can be increased when combined with Ivosidenib. |
| Ixabepilone | The serum concentration of Ixabepilone can be decreased when it is combined with Dabrafenib. |
| Ixazomib | The serum concentration of Ixazomib can be decreased when it is combined with Dabrafenib. |
| Ketamine | The serum concentration of Ketamine can be decreased when it is combined with Dabrafenib. |
| Ketazolam | The serum concentration of Ketazolam can be decreased when it is combined with Dabrafenib. |
| Ketoconazole | The serum concentration of Dabrafenib can be increased when it is combined with Ketoconazole. |
| Ketoprofen | The metabolism of Dabrafenib can be decreased when combined with Ketoprofen. |
| Ketorolac | The serum concentration of Ketorolac can be decreased when it is combined with Dabrafenib. |
| Labetalol | The serum concentration of Labetalol can be decreased when it is combined with Dabrafenib. |
| Lacidipine | The serum concentration of Lacidipine can be decreased when it is combined with Dabrafenib. |
| Lacosamide | The serum concentration of Lacosamide can be decreased when it is combined with Dabrafenib. |
| Lamivudine | Dabrafenib may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
| Lamotrigine | The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Dabrafenib. |
| Lanreotide | The metabolism of Dabrafenib can be decreased when combined with Lanreotide. |
| Lansoprazole | The serum concentration of Lansoprazole can be decreased when it is combined with Dabrafenib. |
| Lapatinib | The serum concentration of Lapatinib can be decreased when it is combined with Dabrafenib. |
| Larotrectinib | The serum concentration of Larotrectinib can be decreased when it is combined with Dabrafenib. |
| Lasmiditan | The serum concentration of Dabrafenib can be increased when it is combined with Lasmiditan. |
| Ledipasvir | The serum concentration of Dabrafenib can be increased when it is combined with Ledipasvir. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Dabrafenib. |
| Leflunomide | The serum concentration of Leflunomide can be decreased when it is combined with Dabrafenib. |
| Lemborexant | The serum concentration of Lemborexant can be increased when it is combined with Dabrafenib. |
| Lenvatinib | Dabrafenib may decrease the excretion rate of Lenvatinib which could result in a higher serum level. |
| Lercanidipine | The serum concentration of Lercanidipine can be decreased when it is combined with Dabrafenib. |
| Lesinurad | The serum concentration of Lesinurad can be decreased when it is combined with Dabrafenib. |
| Letermovir | The metabolism of Dabrafenib can be decreased when combined with Letermovir. |
| Letrozole | The serum concentration of Letrozole can be decreased when it is combined with Dabrafenib. |
| Leucovorin | The excretion of Leucovorin can be decreased when combined with Dabrafenib. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Leuprolide. |
| Levacetylmethadol | The serum concentration of Levacetylmethadol can be decreased when it is combined with Dabrafenib. |
| Levamlodipine | The serum concentration of Levamlodipine can be increased when it is combined with Dabrafenib. |
| Levobupivacaine | The serum concentration of Levobupivacaine can be decreased when it is combined with Dabrafenib. |
| Levocabastine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Dabrafenib. |
| Levocarnitine | The excretion of Levocarnitine can be decreased when combined with Dabrafenib. |
| Levocetirizine | The serum concentration of Levocetirizine can be decreased when it is combined with Dabrafenib. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Levofloxacin. |
| Levoketoconazole | The serum concentration of Dabrafenib can be increased when it is combined with Levoketoconazole. |
| Levomenthol | The serum concentration of Levomenthol can be decreased when it is combined with Dabrafenib. |
| Levomilnacipran | The serum concentration of Levomilnacipran can be decreased when it is combined with Dabrafenib. |
| Levonorgestrel | The serum concentration of Levonorgestrel can be decreased when it is combined with Dabrafenib. |
| Levosalbutamol | The excretion of Levosalbutamol can be decreased when combined with Dabrafenib. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Levosimendan. |
| Levothyroxine | The serum concentration of Dabrafenib can be decreased when it is combined with Levothyroxine. |
| Lidocaine | The serum concentration of Lidocaine can be decreased when it is combined with Dabrafenib. |
| Lidoflazine | The serum concentration of Lidoflazine can be decreased when it is combined with Dabrafenib. |
| Linagliptin | The serum concentration of Linagliptin can be decreased when it is combined with Dabrafenib. |
| Linzagolix | The serum concentration of Dabrafenib can be increased when it is combined with Linzagolix. |
| Liothyronine | The metabolism of Liothyronine can be decreased when combined with Dabrafenib. |
| Liotrix | The serum concentration of Liotrix can be decreased when it is combined with Dabrafenib. |
| Liraglutide | The therapeutic efficacy of Liraglutide can be decreased when used in combination with Dabrafenib. |
| Lisuride | The serum concentration of Lisuride can be decreased when it is combined with Dabrafenib. |
| Lixisenatide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Dabrafenib. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Lofexidine. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Lomefloxacin. |
| Lomitapide | The serum concentration of Lomitapide can be decreased when it is combined with Dabrafenib. |
| Lonafarnib | The serum concentration of Lonafarnib can be increased when it is combined with Dabrafenib. |
| Loncastuximab | The serum concentration of Dabrafenib can be increased when it is combined with Loncastuximab tesirine. |
| Loperamide | The serum concentration of Loperamide can be decreased when it is combined with Dabrafenib. |
| Lopinavir | The serum concentration of Dabrafenib can be increased when it is combined with Lopinavir. |
| Loratadine | The serum concentration of Loratadine can be decreased when it is combined with Dabrafenib. |
| Lorazepam | The serum concentration of Lorazepam can be decreased when it is combined with Dabrafenib. |
| Lorcaserin | The serum concentration of Lorcaserin can be decreased when it is combined with Dabrafenib. |
| Lorlatinib | The serum concentration of Lorlatinib can be decreased when it is combined with Dabrafenib. |
| Lornoxicam | The serum concentration of Lornoxicam can be decreased when it is combined with Dabrafenib. |
| Lorpiprazole | The serum concentration of Lorpiprazole can be decreased when it is combined with Dabrafenib. |
| Losartan | The serum concentration of Losartan can be decreased when it is combined with Dabrafenib. |
| Lovastatin | The metabolism of Lovastatin can be decreased when combined with Dabrafenib. |
| Loxapine | The serum concentration of Dabrafenib can be increased when it is combined with Loxapine. |
| Lumacaftor | The serum concentration of Dabrafenib can be decreased when it is combined with Lumacaftor. |
| Lumateperone | The serum concentration of Lumateperone can be decreased when it is combined with Dabrafenib. |
| Lumefantrine | The serum concentration of Lumefantrine can be decreased when it is combined with Dabrafenib. |
| Lumiracoxib | The serum concentration of Lumiracoxib can be decreased when it is combined with Dabrafenib. |
| Lurasidone | The serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib. |
| Lurbinectedin | The serum concentration of Lurbinectedin can be decreased when it is combined with Dabrafenib. |
| Lusutrombopag | Dabrafenib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. |
| Lynestrenol | The serum concentration of Lynestrenol can be decreased when it is combined with Dabrafenib. |
| Macimorelin | The serum concentration of Macimorelin can be decreased when it is combined with Dabrafenib. |
| Macitentan | The serum concentration of Macitentan can be decreased when it is combined with Dabrafenib. |
| Magaldrate | Magaldrate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium carbonate | Magnesium carbonate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium hydroxide | Magnesium hydroxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium oxide | Magnesium oxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium silicate | Magnesium silicate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium trisilicate | Magnesium trisilicate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Malathion | The serum concentration of Malathion can be decreased when it is combined with Dabrafenib. |
| Manidipine | The serum concentration of Manidipine can be decreased when it is combined with Dabrafenib. |
| Mannitol | The serum concentration of Dabrafenib can be increased when it is combined with Mannitol. |
| Maprotiline | The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Dabrafenib. |
| Maraviroc | The serum concentration of Maraviroc can be decreased when it is combined with Dabrafenib. |
| Maribavir | The serum concentration of Maribavir can be decreased when it is combined with Dabrafenib. |
| Mavacamten | The serum concentration of Mavacamten can be decreased when it is combined with Dabrafenib. |
| Mecasermin | The therapeutic efficacy of Mecasermin can be decreased when used in combination with Dabrafenib. |
| Medrogestone | The serum concentration of Medrogestone can be decreased when it is combined with Dabrafenib. |
| Medroxyprogesterone | The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dabrafenib. |
| Medrysone | The serum concentration of Medrysone can be decreased when it is combined with Dabrafenib. |
| Mefenamic acid | The serum concentration of Mefenamic acid can be decreased when it is combined with Dabrafenib. |
| Mefloquine | The serum concentration of Mefloquine can be decreased when it is combined with Dabrafenib. |
| Megestrol acetate | The serum concentration of Megestrol acetate can be decreased when it is combined with Dabrafenib. |
| Meloxicam | The serum concentration of Meloxicam can be decreased when it is combined with Dabrafenib. |
| Memantine | The serum concentration of Memantine can be increased when it is combined with Dabrafenib. |
| Meperidine | The serum concentration of Meperidine can be decreased when it is combined with Dabrafenib. |
| Mephenytoin | The serum concentration of Mephenytoin can be decreased when it is combined with Dabrafenib. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Mepivacaine. |
| Meprednisone | The serum concentration of Meprednisone can be decreased when it is combined with Dabrafenib. |
| Mepyramine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Dabrafenib. |
| Mercaptopurine | The excretion of Mercaptopurine can be decreased when combined with Dabrafenib. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mesoridazine. |
| Mestranol | The serum concentration of Mestranol can be decreased when it is combined with Dabrafenib. |
| Metformin | The therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib. |
| Methadone | The serum concentration of Methadone can be decreased when it is combined with Dabrafenib. |
| Methantheline | Methantheline can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methimazole | The serum concentration of Dabrafenib can be increased when it is combined with Methimazole. |
| Methotrexate | The serum concentration of Methotrexate can be decreased when it is combined with Dabrafenib. |
| Methotrimeprazine | The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Dabrafenib. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dabrafenib. |
| Methoxyflurane | The serum concentration of Methoxyflurane can be decreased when it is combined with Dabrafenib. |
| Methsuximide | The serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib. |
| Methylene blue | The serum concentration of Methylene blue can be decreased when it is combined with Dabrafenib. |
| Methylergometrine | The serum concentration of Methylergometrine can be decreased when it is combined with Dabrafenib. |
| Methylphenobarbital | The serum concentration of Methylphenobarbital can be decreased when it is combined with Dabrafenib. |
| Methylprednisolone | The serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib. |
| Methylprednisone | The serum concentration of Methylprednisone can be decreased when it is combined with Dabrafenib. |
| Methyltestosterone | The serum concentration of Methyltestosterone can be decreased when it is combined with Dabrafenib. |
| Methysergide | The serum concentration of Methysergide can be decreased when it is combined with Dabrafenib. |
| Metoclopramide | The serum concentration of Metoclopramide can be decreased when it is combined with Dabrafenib. |
| Metreleptin | The metabolism of Dabrafenib can be increased when combined with Metreleptin. |
| Metronidazole | The metabolism of Dabrafenib can be decreased when combined with Metronidazole. |
| Metyrapone | The metabolism of Dabrafenib can be increased when combined with Metyrapone. |
| Mexiletine | The serum concentration of Mexiletine can be decreased when it is combined with Dabrafenib. |
| Mianserin | The serum concentration of Mianserin can be decreased when it is combined with Dabrafenib. |
| Miconazole | The metabolism of Dabrafenib can be decreased when combined with Miconazole. |
| Midazolam | The serum concentration of Midazolam can be decreased when it is combined with Dabrafenib. |
| Midostaurin | The serum concentration of Dabrafenib can be increased when it is combined with Midostaurin. |
| Mifepristone | The serum concentration of Dabrafenib can be increased when it is combined with Mifepristone. |
| Migalastat | The metabolism of Migalastat can be decreased when combined with Dabrafenib. |
| Miglitol | The therapeutic efficacy of Miglitol can be decreased when used in combination with Dabrafenib. |
| Milnacipran | The serum concentration of Milnacipran can be decreased when it is combined with Dabrafenib. |
| Minoxidil | The metabolism of Minoxidil can be decreased when combined with Dabrafenib. |
| Miocamycin | The metabolism of Dabrafenib can be decreased when combined with Miocamycin. |
| Mirabegron | The serum concentration of Mirabegron can be decreased when it is combined with Dabrafenib. |
| Mirtazapine | The serum concentration of Mirtazapine can be decreased when it is combined with Dabrafenib. |
| Mitapivat | The serum concentration of Mitapivat can be decreased when it is combined with Dabrafenib. |
| Mitotane | The serum concentration of Dabrafenib can be decreased when it is combined with Mitotane. |
| Mitoxantrone | Dabrafenib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. |
| Mizolastine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mizolastine. |
| Mobocertinib | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mobocertinib. |
| Moclobemide | The serum concentration of Moclobemide can be decreased when it is combined with Dabrafenib. |
| Modafinil | The serum concentration of Modafinil can be decreased when it is combined with Dabrafenib. |
| Moexipril | The risk or severity of QTc prolongation can be increased when Moexipril is combined with Dabrafenib. |
| Mometasone furoate | The serum concentration of Dabrafenib can be increased when it is combined with Mometasone furoate. |
| Montelukast | The serum concentration of Montelukast can be decreased when it is combined with Dabrafenib. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Moricizine is combined with Dabrafenib. |
| Morphine | The serum concentration of Morphine can be decreased when it is combined with Dabrafenib. |
| Mosunetuzumab | The metabolism of Dabrafenib can be decreased when combined with Mosunetuzumab. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Moxifloxacin. |
| Mycophenolate mofetil | The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dabrafenib. |
| Mycophenolic acid | The metabolism of Mycophenolic acid can be decreased when combined with Dabrafenib. |
| Nabilone | The serum concentration of Nabilone can be decreased when it is combined with Dabrafenib. |
| Nabumetone | The serum concentration of Nabumetone can be decreased when it is combined with Dabrafenib. |
| Nafcillin | The metabolism of Dabrafenib can be increased when combined with Nafcillin. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Nalidixic acid. |
| Naloxegol | The serum concentration of Naloxegol can be decreased when it is combined with Dabrafenib. |
| Naloxone | The serum concentration of Dabrafenib can be increased when it is combined with Naloxone. |
| Naltrexone | The metabolism of Naltrexone can be decreased when combined with Dabrafenib. |
| Naproxen | The serum concentration of Naproxen can be decreased when it is combined with Dabrafenib. |
| Nateglinide | The serum concentration of Nateglinide can be decreased when it is combined with Dabrafenib. |
| Nebivolol | The serum concentration of Nebivolol can be decreased when it is combined with Dabrafenib. |
| Nefazodone | The serum concentration of Dabrafenib can be increased when it is combined with Nefazodone. |
| Nelfinavir | The serum concentration of Dabrafenib can be increased when it is combined with Nelfinavir. |
| Neratinib | The serum concentration of Neratinib can be decreased when it is combined with Dabrafenib. |
| Netupitant | The serum concentration of Netupitant can be decreased when it is combined with Dabrafenib. |
| Nevirapine | The serum concentration of Nevirapine can be decreased when it is combined with Dabrafenib. |
| Niacin | The metabolism of Dabrafenib can be decreased when combined with Niacin. |
| Nicardipine | The serum concentration of Nicardipine can be decreased when it is combined with Dabrafenib. |
| Niclosamide | The serum concentration of Niclosamide can be decreased when it is combined with Dabrafenib. |
| Nicotine | The serum concentration of Nicotine can be decreased when it is combined with Dabrafenib. |
| Nifedipine | The serum concentration of Nifedipine can be decreased when it is combined with Dabrafenib. |
| Nilotinib | The serum concentration of Dabrafenib can be increased when it is combined with Nilotinib. |
| Nilutamide | The serum concentration of Nilutamide can be decreased when it is combined with Dabrafenib. |
| Nilvadipine | The serum concentration of Nilvadipine can be decreased when it is combined with Dabrafenib. |
| Nimesulide | The serum concentration of Nimesulide can be decreased when it is combined with Dabrafenib. |
| Nimodipine | The serum concentration of Nimodipine can be decreased when it is combined with Dabrafenib. |
| Nintedanib | The serum concentration of Nintedanib can be decreased when it is combined with Dabrafenib. |
| Nirmatrelvir | The serum concentration of Nirmatrelvir can be decreased when it is combined with Dabrafenib. |
| Nisoldipine | The serum concentration of Nisoldipine can be decreased when it is combined with Dabrafenib. |
| Nitrazepam | The serum concentration of Nitrazepam can be decreased when it is combined with Dabrafenib. |
| Nitrendipine | The serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib. |
| Nitrofurantoin | Dabrafenib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
| Nizatidine | Nizatidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nomegestrol | The serum concentration of Nomegestrol can be decreased when it is combined with Dabrafenib. |
| Nomegestrol acetate | The serum concentration of Nomegestrol acetate can be decreased when it is combined with Dabrafenib. |
| Norelgestromin | The serum concentration of Norelgestromin can be decreased when it is combined with Dabrafenib. |
| Norepinephrine | The serum concentration of Norepinephrine can be increased when it is combined with Dabrafenib. |
| Norethisterone | The serum concentration of Norethisterone can be decreased when it is combined with Dabrafenib. |
| Norethynodrel | The serum concentration of Norethynodrel can be decreased when it is combined with Dabrafenib. |
| Norfloxacin | The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Dabrafenib. |
| Norgestimate | The serum concentration of Norgestimate can be decreased when it is combined with Dabrafenib. |
| Norgestrel | The serum concentration of Norgestrel can be decreased when it is combined with Dabrafenib. |
| Nortriptyline | The serum concentration of Nortriptyline can be decreased when it is combined with Dabrafenib. |
| Noscapine | The metabolism of Dabrafenib can be decreased when combined with Noscapine. |
| Novobiocin | Novobiocin may decrease the excretion rate of Dabrafenib which could result in a higher serum level. |
| Nylidrin | The serum concentration of Nylidrin can be decreased when it is combined with Dabrafenib. |
| Octreotide | The serum concentration of Dabrafenib can be increased when it is combined with Octreotide. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ofloxacin. |
| Olanzapine | Olanzapine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Olaparib | The serum concentration of Olaparib can be decreased when it is combined with Dabrafenib. |
| Oliceridine | The serum concentration of Oliceridine can be decreased when it is combined with Dabrafenib. |
| Olodaterol | The serum concentration of Olodaterol can be decreased when it is combined with Dabrafenib. |
| Omadacycline | The serum concentration of Dabrafenib can be increased when it is combined with Omadacycline. |
| Ombitasvir | The serum concentration of Ombitasvir can be decreased when it is combined with Dabrafenib. |
| Omeprazole | The serum concentration of Omeprazole can be decreased when it is combined with Dabrafenib. |
| Ondansetron | The serum concentration of Ondansetron can be decreased when it is combined with Dabrafenib. |
| Opium | The serum concentration of Opium can be decreased when it is combined with Dabrafenib. |
| Oritavancin | The metabolism of Dabrafenib can be increased when combined with Oritavancin. |
| Orphenadrine | The serum concentration of Orphenadrine can be decreased when it is combined with Dabrafenib. |
| Oseltamivir | The excretion of Oseltamivir can be decreased when combined with Dabrafenib. |
| Osilodrostat | The serum concentration of Osilodrostat can be decreased when it is combined with Dabrafenib. |
| Osimertinib | The serum concentration of Osimertinib can be decreased when it is combined with Dabrafenib. |
| Ospemifene | The serum concentration of Ospemifene can be decreased when it is combined with Dabrafenib. |
| Oteseconazole | The serum concentration of Dabrafenib can be increased when it is combined with Oteseconazole. |
| Ouabain | The excretion of Ouabain can be decreased when combined with Dabrafenib. |
| Oxaliplatin | The serum concentration of Oxaliplatin can be increased when it is combined with Dabrafenib. |
| Oxandrolone | The metabolism of Dabrafenib can be decreased when combined with Oxandrolone. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Oxatomide. |
| Oxcarbazepine | The metabolism of Dabrafenib can be increased when combined with Oxcarbazepine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Oxybuprocaine. |
| Oxybutynin | The serum concentration of Oxybutynin can be decreased when it is combined with Dabrafenib. |
| Oxycodone | The serum concentration of Oxycodone can be decreased when it is combined with Dabrafenib. |
| Oxymorphone | The serum concentration of Oxymorphone can be decreased when it is combined with Dabrafenib. |
| Oxytetracycline | The excretion of Oxytetracycline can be decreased when combined with Dabrafenib. |
| Oxytocin | The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dabrafenib. |
| Ozanimod | The metabolism of Ozanimod can be decreased when combined with Dabrafenib. |
| Paclitaxel | The serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib. |
| Pacritinib | The serum concentration of Dabrafenib can be increased when it is combined with Pacritinib. |
| Padeliporfin | Dabrafenib may increase the photosensitizing activities of Padeliporfin. |
| Palbociclib | The serum concentration of Palbociclib can be decreased when it is combined with Dabrafenib. |
| Paliperidone | The serum concentration of Paliperidone can be decreased when it is combined with Dabrafenib. |
| Palonosetron | The serum concentration of Palonosetron can be decreased when it is combined with Dabrafenib. |
| Palovarotene | The serum concentration of Palovarotene can be decreased when it is combined with Dabrafenib. |
| Panobinostat | The serum concentration of Panobinostat can be decreased when it is combined with Dabrafenib. |
| Pantoprazole | The serum concentration of Pantoprazole can be decreased when it is combined with Dabrafenib. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Papaverine. |
| Paramethadione | The serum concentration of Paramethadione can be decreased when it is combined with Dabrafenib. |
| Parecoxib | The serum concentration of Parecoxib can be decreased when it is combined with Dabrafenib. |
| Paricalcitol | The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. |
| Paritaprevir | The serum concentration of Paritaprevir can be decreased when it is combined with Dabrafenib. |
| Paroxetine | The serum concentration of Paroxetine can be decreased when it is combined with Dabrafenib. |
| Pasireotide | The metabolism of Dabrafenib can be decreased when combined with Pasireotide. |
| Pazopanib | The serum concentration of Pazopanib can be decreased when it is combined with Dabrafenib. |
| Pefloxacin | The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Dabrafenib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Dabrafenib. |
| Peginterferon alfa-2b | The metabolism of Dabrafenib can be increased when combined with Peginterferon alfa-2b. |
| Pemetrexed | Dabrafenib may decrease the excretion rate of Pemetrexed which could result in a higher serum level. |
| Pemigatinib | The serum concentration of Pemigatinib can be decreased when it is combined with Dabrafenib. |
| Penicillamine | The excretion of Penicillamine can be decreased when combined with Dabrafenib. |
| Pentamidine | The serum concentration of Pentamidine can be decreased when it is combined with Dabrafenib. |
| Pentobarbital | The serum concentration of Pentobarbital can be decreased when it is combined with Dabrafenib. |
| Perampanel | The metabolism of Perampanel can be increased when combined with Dabrafenib. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Perflutren. |
| Perhexiline | The serum concentration of Perhexiline can be decreased when it is combined with Dabrafenib. |
| Pexidartinib | The metabolism of Pexidartinib can be increased when combined with Dabrafenib. |
| Phenformin | The therapeutic efficacy of Phenformin can be decreased when used in combination with Dabrafenib. |
| Pheniramine | The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dabrafenib. |
| Phenobarbital | The serum concentration of Phenobarbital can be decreased when it is combined with Dabrafenib. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Phenol. |
| Phenprocoumon | The serum concentration of Phenprocoumon can be decreased when it is combined with Dabrafenib. |
| Phentermine | The serum concentration of Phentermine can be decreased when it is combined with Dabrafenib. |
| Phenylbutazone | The serum concentration of Phenylbutazone can be decreased when it is combined with Dabrafenib. |
| Phenytoin | The serum concentration of Phenytoin can be decreased when it is combined with Dabrafenib. |
| Pibrentasvir | The serum concentration of Dabrafenib can be increased when it is combined with Pibrentasvir. |
| Pimavanserin | The serum concentration of Pimavanserin can be decreased when it is combined with Dabrafenib. |
| Pimecrolimus | The serum concentration of Pimecrolimus can be decreased when it is combined with Dabrafenib. |
| Pimozide | The serum concentration of Pimozide can be decreased when it is combined with Dabrafenib. |
| Pinacidil | The serum concentration of Pinacidil can be decreased when it is combined with Dabrafenib. |
| Pinaverium | The serum concentration of Pinaverium can be decreased when it is combined with Dabrafenib. |
| Pioglitazone | The serum concentration of Pioglitazone can be increased when it is combined with Dabrafenib. |
| Piperacillin | The excretion of Piperacillin can be decreased when combined with Dabrafenib. |
| Piperaquine | The serum concentration of Piperaquine can be decreased when it is combined with Dabrafenib. |
| Pipotiazine | The serum concentration of Pipotiazine can be decreased when it is combined with Dabrafenib. |
| Pirfenidone | The serum concentration of Pirfenidone can be decreased when it is combined with Dabrafenib. |
| Piroxicam | The serum concentration of Piroxicam can be decreased when it is combined with Dabrafenib. |
| Pitavastatin | The serum concentration of Pitavastatin can be decreased when it is combined with Dabrafenib. |
| Pitolisant | The serum concentration of Dabrafenib can be decreased when it is combined with Pitolisant. |
| Polatuzumab | The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Dabrafenib. |
| Polythiazide | The excretion of Polythiazide can be decreased when combined with Dabrafenib. |
| Pomalidomide | The serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib. |
| Ponatinib | The serum concentration of Ponatinib can be decreased when it is combined with Dabrafenib. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Dabrafenib. |
| Porfimer sodium | Dabrafenib may increase the photosensitizing activities of Porfimer sodium. |
| Posaconazole | The serum concentration of Dabrafenib can be increased when it is combined with Posaconazole. |
| Pralatrexate | Dabrafenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
| Pralsetinib | The serum concentration of Pralsetinib can be decreased when it is combined with Dabrafenib. |
| Pramipexole | The serum concentration of Pramipexole can be increased when it is combined with Dabrafenib. |
| Pramlintide | The therapeutic efficacy of Pramlintide can be decreased when used in combination with Dabrafenib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Pramocaine. |
| Prasterone | The serum concentration of Prasterone can be decreased when it is combined with Dabrafenib. |
| Prasugrel | The serum concentration of Prasugrel can be decreased when it is combined with Dabrafenib. |
| Pravastatin | The excretion of Pravastatin can be decreased when combined with Dabrafenib. |
| Prazepam | The serum concentration of Prazepam can be decreased when it is combined with Dabrafenib. |
| Praziquantel | The serum concentration of Praziquantel can be decreased when it is combined with Dabrafenib. |
| Prazosin | Dabrafenib may decrease the excretion rate of Prazosin which could result in a higher serum level. |
| Prednicarbate | The serum concentration of Prednicarbate can be decreased when it is combined with Dabrafenib. |
| Prednisolone | The serum concentration of Prednisolone can be decreased when it is combined with Dabrafenib. |
| Prednisolone | The serum concentration of Prednisolone acetate can be decreased when it is combined with Dabrafenib. |
| Prednisolone | The serum concentration of Prednisolone phosphate can be decreased when it is combined with Dabrafenib. |
| Prednisone | The serum concentration of Prednisone can be decreased when it is combined with Dabrafenib. |
| Prednisone acetate | The metabolism of Dabrafenib can be increased when combined with Prednisone acetate. |
| Pregabalin | The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Dabrafenib. |
| Pregnenolone | The serum concentration of Pregnenolone can be decreased when it is combined with Dabrafenib. |
| Prenylamine | The serum concentration of Prenylamine can be decreased when it is combined with Dabrafenib. |
| Pretomanid | The serum concentration of Pretomanid can be decreased when it is combined with Dabrafenib. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Prilocaine. |
| Primaquine | The serum concentration of Primaquine can be decreased when it is combined with Dabrafenib. |
| Primidone | The serum concentration of Primidone can be decreased when it is combined with Dabrafenib. |
| Probenecid | The metabolism of Dabrafenib can be increased when combined with Probenecid. |
| Probucol | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Probucol. |
| Procainamide | The serum concentration of Procainamide can be increased when it is combined with Dabrafenib. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Procaine. |
| Prochlorperazine | The serum concentration of Prochlorperazine can be decreased when it is combined with Dabrafenib. |
| Progesterone | The serum concentration of Progesterone can be decreased when it is combined with Dabrafenib. |
| Proguanil | The serum concentration of Proguanil can be decreased when it is combined with Dabrafenib. |
| Promazine | The serum concentration of Promazine can be decreased when it is combined with Dabrafenib. |
| Promethazine | The serum concentration of Promethazine can be decreased when it is combined with Dabrafenib. |
| Propafenone | The serum concentration of Propafenone can be decreased when it is combined with Dabrafenib. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Proparacaine. |
| Propiverine | The serum concentration of Propiverine can be decreased when it is combined with Dabrafenib. |
| Propofol | The serum concentration of Propofol can be decreased when it is combined with Dabrafenib. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Propoxycaine. |
| Propranolol | The serum concentration of Propranolol can be decreased when it is combined with Dabrafenib. |
| Protriptyline | The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Dabrafenib. |
| Prucalopride | The serum concentration of Prucalopride can be decreased when it is combined with Dabrafenib. |
| Pyrimethamine | The metabolism of Dabrafenib can be decreased when combined with Pyrimethamine. |
| Quazepam | The serum concentration of Quazepam can be decreased when it is combined with Dabrafenib. |
| Quetiapine | The serum concentration of Quetiapine can be decreased when it is combined with Dabrafenib. |
| Quinapril | The excretion of Quinapril can be decreased when combined with Dabrafenib. |
| Quinidine | The serum concentration of Quinidine can be decreased when it is combined with Dabrafenib. |
| Quinine | The serum concentration of Quinine can be decreased when it is combined with Dabrafenib. |
| Quinupristin | The metabolism of Dabrafenib can be decreased when combined with Quinupristin. |
| Rabeprazole | The serum concentration of Rabeprazole can be decreased when it is combined with Dabrafenib. |
| Raloxifene | The metabolism of Dabrafenib can be decreased when combined with Raloxifene. |
| Raltegravir | The metabolism of Raltegravir can be decreased when combined with Dabrafenib. |
| Ramelteon | The serum concentration of Ramelteon can be decreased when it is combined with Dabrafenib. |
| Ranitidine | Ranitidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ranolazine | The metabolism of Ranolazine can be increased when combined with Dabrafenib. |
| Reboxetine | The serum concentration of Reboxetine can be decreased when it is combined with Dabrafenib. |
| Regorafenib | The serum concentration of Regorafenib can be decreased when it is combined with Dabrafenib. |
| Relebactam | The excretion of Relebactam can be decreased when combined with Dabrafenib. |
| Relugolix | The serum concentration of Relugolix can be decreased when it is combined with Dabrafenib. |
| Remdesivir | The serum concentration of Remdesivir can be decreased when it is combined with Dabrafenib. |
| Repaglinide | The serum concentration of Repaglinide can be decreased when it is combined with Dabrafenib. |
| Reserpine | The serum concentration of Dabrafenib can be increased when it is combined with Reserpine. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Dabrafenib. |
| Revefenacin | Dabrafenib may decrease the excretion rate of Revefenacin which could result in a higher serum level. |
| Ribociclib | The serum concentration of Dabrafenib can be increased when it is combined with Ribociclib. |
| Rifabutin | The serum concentration of Rifabutin can be decreased when it is combined with Dabrafenib. |
| Rifampicin | The serum concentration of Dabrafenib can be decreased when it is combined with Rifampicin. |
| Rifamycin | The serum concentration of Dabrafenib can be decreased when it is combined with Rifamycin. |
| Rifapentine | The serum concentration of Rifapentine can be decreased when it is combined with Dabrafenib. |
| Rilonacept | The metabolism of Dabrafenib can be increased when combined with Rilonacept. |
| Rilpivirine | The serum concentration of Rilpivirine can be decreased when it is combined with Dabrafenib. |
| Riluzole | Dabrafenib may decrease the excretion rate of Riluzole which could result in a higher serum level. |
| Rimegepant | The metabolism of Rimegepant can be increased when combined with Dabrafenib. |
| Rimexolone | The serum concentration of Rimexolone can be decreased when it is combined with Dabrafenib. |
| Rimonabant | The serum concentration of Rimonabant can be decreased when it is combined with Dabrafenib. |
| Riociguat | The serum concentration of Riociguat can be decreased when it is combined with Dabrafenib. |
| Ripretinib | The serum concentration of Ripretinib can be decreased when it is combined with Dabrafenib. |
| Risperidone | The serum concentration of Risperidone can be decreased when it is combined with Dabrafenib. |
| Ritonavir | The serum concentration of Dabrafenib can be increased when it is combined with Ritonavir. |
| Rivaroxaban | The serum concentration of Rivaroxaban can be decreased when it is combined with Dabrafenib. |
| Rofecoxib | The serum concentration of Rofecoxib can be decreased when it is combined with Dabrafenib. |
| Roflumilast | The serum concentration of Roflumilast can be decreased when it is combined with Dabrafenib. |
| Rolapitant | The serum concentration of Rolapitant can be decreased when it is combined with Dabrafenib. |
| Romidepsin | The serum concentration of Romidepsin can be decreased when it is combined with Dabrafenib. |
| Ropinirole | The risk or severity of adverse effects can be increased when Dabrafenib is combined with Ropinirole. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Ropivacaine. |
| Rosiglitazone | The serum concentration of Rosiglitazone can be decreased when it is combined with Dabrafenib. |
| Rosoxacin | The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Dabrafenib. |
| Rosuvastatin | The serum concentration of Rosuvastatin can be decreased when it is combined with Dabrafenib. |
| Rotigotine | The serum concentration of Rotigotine can be decreased when it is combined with Dabrafenib. |
| Roxadustat | The metabolism of Roxadustat can be decreased when combined with Dabrafenib. |
| Roxithromycin | The serum concentration of Roxithromycin can be decreased when it is combined with Dabrafenib. |
| Rucaparib | The serum concentration of Rucaparib can be decreased when it is combined with Dabrafenib. |
| Rufinamide | The metabolism of Dabrafenib can be increased when combined with Rufinamide. |
| Rupatadine | The serum concentration of Rupatadine can be decreased when it is combined with Dabrafenib. |
| Ruxolitinib | The serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib. |
| Sacituzumab govitecan | The serum concentration of Sacituzumab govitecan can be increased when it is combined with Dabrafenib. |
| Safinamide | The serum concentration of Safinamide can be decreased when it is combined with Dabrafenib. |
| Salbutamol | The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dabrafenib. |
| Salicylic acid | The serum concentration of Salicylic acid can be decreased when it is combined with Dabrafenib. |
| Salmeterol | The serum concentration of Dabrafenib can be increased when it is combined with Salmeterol. |
| Samidorphan | The serum concentration of Samidorphan can be decreased when it is combined with Dabrafenib. |
| Sapropterin | The serum concentration of Dabrafenib can be increased when it is combined with Sapropterin. |
| Saquinavir | The serum concentration of Dabrafenib can be increased when it is combined with Saquinavir. |
| Sarecycline | The serum concentration of Dabrafenib can be increased when it is combined with Sarecycline. |
| Sarilumab | The metabolism of Dabrafenib can be increased when combined with Sarilumab. |
| Satralizumab | The serum concentration of Dabrafenib can be decreased when it is combined with Satralizumab. |
| Saxagliptin | The serum concentration of Saxagliptin can be decreased when it is combined with Dabrafenib. |
| Scopolamine | The serum concentration of Scopolamine can be decreased when it is combined with Dabrafenib. |
| Secobarbital | The serum concentration of Dabrafenib can be decreased when it is combined with Secobarbital. |
| Secukinumab | The metabolism of Dabrafenib can be increased when combined with Secukinumab. |
| Segesterone | The metabolism of Segesterone acetate can be increased when combined with Dabrafenib. |
| Selegiline | The serum concentration of Selegiline can be decreased when it is combined with Dabrafenib. |
| Selexipag | The serum concentration of Selexipag can be decreased when it is combined with Dabrafenib. |
| Selinexor | The serum concentration of Selinexor can be decreased when it is combined with Dabrafenib. |
| Selpercatinib | The serum concentration of Selpercatinib can be increased when it is combined with Dabrafenib. |
| Selumetinib | The serum concentration of Selumetinib can be decreased when it is combined with Dabrafenib. |
| Semaglutide | The therapeutic efficacy of Semaglutide can be decreased when used in combination with Dabrafenib. |
| Sertindole | The serum concentration of Sertindole can be decreased when it is combined with Dabrafenib. |
| Sertraline | The serum concentration of Sertraline can be decreased when it is combined with Dabrafenib. |
| Sevoflurane | The serum concentration of Sevoflurane can be decreased when it is combined with Dabrafenib. |
| Sibutramine | The serum concentration of Sibutramine can be decreased when it is combined with Dabrafenib. |
| Sildenafil | The serum concentration of Sildenafil can be decreased when it is combined with Dabrafenib. |
| Silodosin | The serum concentration of Silodosin can be decreased when it is combined with Dabrafenib. |
| Siltuximab | The metabolism of Dabrafenib can be increased when combined with Siltuximab. |
| Simeprevir | The serum concentration of Simeprevir can be decreased when it is combined with Dabrafenib. |
| Simvastatin | The serum concentration of Simvastatin can be decreased when it is combined with Dabrafenib. |
| Sincalide | The excretion of Sincalide can be decreased when combined with Dabrafenib. |
| Siponimod | The serum concentration of Siponimod can be decreased when it is combined with Dabrafenib. |
| Sirolimus | The serum concentration of Sirolimus can be decreased when it is combined with Dabrafenib. |
| Sitagliptin | The serum concentration of Sitagliptin can be decreased when it is combined with Dabrafenib. |
| Sitaxentan | The serum concentration of Sitaxentan can be decreased when it is combined with Dabrafenib. |
| Sodium | Sodium bicarbonate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Solifenacin | The serum concentration of Solifenacin can be decreased when it is combined with Dabrafenib. |
| Solriamfetol | The serum concentration of Solriamfetol can be increased when it is combined with Dabrafenib. |
| Somatostatin | The metabolism of Dabrafenib can be decreased when combined with Somatostatin. |
| Somatrogon | The metabolism of Dabrafenib can be increased when combined with Somatrogon. |
| Sonidegib | The serum concentration of Sonidegib can be decreased when it is combined with Dabrafenib. |
| Sorafenib | The serum concentration of Dabrafenib can be increased when it is combined with Sorafenib. |
| Sotagliflozin | The serum concentration of Dabrafenib can be increased when it is combined with Sotagliflozin. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sotalol. |
| Sotorasib | The serum concentration of Dabrafenib can be decreased when it is combined with Sotorasib. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sparfloxacin. |
| Spironolactone | The metabolism of Dabrafenib can be decreased when combined with Spironolactone. |
| St. John’s Wort | The serum concentration of St. John’s Wort can be decreased when it is combined with Dabrafenib. |
| Stavudine | The excretion of Stavudine can be decreased when combined with Dabrafenib. |
| Stiripentol | The metabolism of Dabrafenib can be decreased when combined with Stiripentol. |
| Succinic acid | The excretion of Succinic acid can be decreased when combined with Dabrafenib. |
| Sufentanil | The serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib. |
| Sulfadiazine | The serum concentration of Sulfadiazine can be decreased when it is combined with Dabrafenib. |
| Sulfamethizole | The metabolism of Dabrafenib can be decreased when combined with Sulfamethizole. |
| Sulfamethoxazole | The serum concentration of Sulfamethoxazole can be decreased when it is combined with Dabrafenib. |
| Sulfaphenazole | The metabolism of Dabrafenib can be decreased when combined with Sulfaphenazole. |
| Sulfapyridine | The metabolism of Dabrafenib can be decreased when combined with Sulfapyridine. |
| Sulfasalazine | Sulfasalazine may decrease the excretion rate of Dabrafenib which could result in a higher serum level. |
| Sulfinpyrazone | The serum concentration of Sulfinpyrazone can be decreased when it is combined with Dabrafenib. |
| Sulfisoxazole | The metabolism of Dabrafenib can be decreased when combined with Sulfisoxazole. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sulpiride. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sultopride. |
| Sumatriptan | Dabrafenib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. |
| Sunitinib | The serum concentration of Sunitinib can be decreased when it is combined with Dabrafenib. |
| Suprofen | The serum concentration of Suprofen can be decreased when it is combined with Dabrafenib. |
| Suvorexant | The serum concentration of Suvorexant can be decreased when it is combined with Dabrafenib. |
| Estrogens, A | The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Dabrafenib. |
| SEstrogens, | The serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Dabrafenib. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Dabrafenib. |
| Tadalafil | The serum concentration of Tadalafil can be decreased when it is combined with Dabrafenib. |
| Tafamidis | The serum concentration of Dabrafenib can be increased when it is combined with Tafamidis. |
| Talazoparib | Dabrafenib may decrease the excretion rate of Talazoparib which could result in a higher serum level. |
| Tamoxifen | The serum concentration of Tamoxifen can be decreased when it is combined with Dabrafenib. |
| Tamsulosin | The serum concentration of Tamsulosin can be decreased when it is combined with Dabrafenib. |
| Tasimelteon | The serum concentration of Tasimelteon can be decreased when it is combined with Dabrafenib. |
| Taurocholic acid | The excretion of Taurocholic acid can be decreased when combined with Dabrafenib. |
| Tazarotene | The serum concentration of Tazarotene can be decreased when it is combined with Dabrafenib. |
| Tazemetostat | The serum concentration of Tazemetostat can be decreased when it is combined with Dabrafenib. |
| Tazobactam | The excretion of Tazobactam can be decreased when combined with Dabrafenib. |
| Technetium | The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Dabrafenib. |
| Technetium | The serum concentration of Dabrafenib can be increased when it is combined with Technetium Tc-99m sestamibi. |
| Tecovirimat | The metabolism of Dabrafenib can be increased when combined with Tecovirimat. |
| Tegafur | The serum concentration of Tegafur can be decreased when it is combined with Dabrafenib. |
| Tegaserod | The metabolism of Dabrafenib can be decreased when combined with Tegaserod. |
| Telaprevir | The serum concentration of Dabrafenib can be increased when it is combined with Telaprevir. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Telavancin. |
| Telithromycin | The serum concentration of Dabrafenib can be increased when it is combined with Telithromycin. |
| Telmisartan | Telmisartan may decrease the excretion rate of Dabrafenib which could result in a higher serum level. |
| Telotristat ethyl | The serum concentration of Dabrafenib can be decreased when it is combined with Telotristat ethyl. |
| Temsirolimus | The serum concentration of Temsirolimus can be decreased when it is combined with Dabrafenib. |
| Teniposide | The serum concentration of Teniposide can be decreased when it is combined with Dabrafenib. |
| Tenofovir alafenamide | The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Dabrafenib. |
| Tenofovir disoproxil | The excretion of Tenofovir disoproxil can be decreased when combined with Dabrafenib. |
| Tenoxicam | The serum concentration of Tenoxicam can be decreased when it is combined with Dabrafenib. |
| Tepotinib | The serum concentration of Dabrafenib can be increased when it is combined with Tepotinib. |
| Terbinafine | The serum concentration of Terbinafine can be decreased when it is combined with Dabrafenib. |
| Terbutaline | The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dabrafenib. |
| Terfenadine | The serum concentration of Dabrafenib can be increased when it is combined with Terfenadine. |
| Teriflunomide | The metabolism of Dabrafenib can be decreased when combined with Teriflunomide. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Terlipressin. |
| Testosterone | The serum concentration of Testosterone can be decreased when it is combined with Dabrafenib. |
| Testosterone | The serum concentration of Testosterone cypionate can be decreased when it is combined with Dabrafenib. |
| Testosterone | The serum concentration of Testosterone enanthate can be decreased when it is combined with Dabrafenib. |
| Testosterone | The serum concentration of Testosterone propionate can be decreased when it is combined with Dabrafenib. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Tetrabenazine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Tetracaine. |
| Tetracycline | The serum concentration of Tetracycline can be decreased when it is combined with Dabrafenib. |
| Tezacaftor | The serum concentration of Tezacaftor can be decreased when it is combined with Dabrafenib. |
| Thalidomide | The serum concentration of Thalidomide can be decreased when it is combined with Dabrafenib. |
| Theophylline | The serum concentration of Theophylline can be decreased when it is combined with Dabrafenib. |
| Thiamylal | The serum concentration of Thiamylal can be decreased when it is combined with Dabrafenib. |
| Thiopental | The serum concentration of Thiopental can be decreased when it is combined with Dabrafenib. |
| Thioridazine | The serum concentration of Thioridazine can be decreased when it is combined with Dabrafenib. |
| Thiotepa | The serum concentration of Thiotepa can be decreased when it is combined with Dabrafenib. |
| Thiothixene | The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Dabrafenib. |
| Tiagabine | The serum concentration of Tiagabine can be decreased when it is combined with Dabrafenib. |
| Ticagrelor | The serum concentration of Ticagrelor can be decreased when it is combined with Dabrafenib. |
| Ticlopidine | The serum concentration of Ticlopidine can be decreased when it is combined with Dabrafenib. |
| Timolol | The serum concentration of Timolol can be decreased when it is combined with Dabrafenib. |
| Tinidazole | The serum concentration of Tinidazole can be decreased when it is combined with Dabrafenib. |
| Tiotropium | The serum concentration of Tiotropium can be decreased when it is combined with Dabrafenib. |
| Tipiracil | The excretion of Tipiracil can be decreased when combined with Dabrafenib. |
| Tipranavir | The serum concentration of Dabrafenib can be increased when it is combined with Tipranavir. |
| Tirzepatide | The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Dabrafenib. |
| Tisotumab vedotin | The serum concentration of Tisotumab vedotin can be decreased when it is combined with Dabrafenib. |
| Tivozanib | The metabolism of Tivozanib can be increased when combined with Dabrafenib. |
| Tizanidine | The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Dabrafenib. |
| Tocilizumab | The metabolism of Dabrafenib can be increased when combined with Tocilizumab. |
| Tocofersolan | The serum concentration of Tocofersolan can be decreased when it is combined with Dabrafenib. |
| Tocopherol | The serum concentration of Tocopherol can be decreased when it is combined with Dabrafenib. |
| Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with Dabrafenib. |
| Tolazamide | The serum concentration of Tolazamide can be decreased when it is combined with Dabrafenib. |
| Tolbutamide | The serum concentration of Tolbutamide can be decreased when it is combined with Dabrafenib. |
| Tolfenamic acid | The serum concentration of Tolfenamic acid can be decreased when it is combined with Dabrafenib. |
| Tolterodine | The serum concentration of Tolterodine can be decreased when it is combined with Dabrafenib. |
| Tolvaptan | The serum concentration of Tolvaptan can be decreased when it is combined with Dabrafenib. |
| Topiramate | The metabolism of Dabrafenib can be increased when combined with Topiramate. |
| Topotecan | Dabrafenib may decrease the excretion rate of Topotecan which could result in a higher serum level. |
| Torasemide | The serum concentration of Torasemide can be decreased when it is combined with Dabrafenib. |
| Toremifene | The serum concentration of Toremifene can be decreased when it is combined with Dabrafenib. |
| Trabectedin | The serum concentration of Trabectedin can be decreased when it is combined with Dabrafenib. |
| Tramadol | The metabolism of Tramadol can be decreased when combined with Dabrafenib. |
| Trametinib | The risk or severity of adverse effects can be increased when Trametinib is combined with Dabrafenib. |
| Tranylcypromine | The metabolism of Dabrafenib can be decreased when combined with Tranylcypromine. |
| Trastuzumab emtansine | The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Dabrafenib. |
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dabrafenib. |
| Treprostinil | The serum concentration of Treprostinil can be increased when it is combined with Dabrafenib. |
| Tretinoin | The risk or severity of adverse effects can be increased when Tretinoin is combined with Dabrafenib. |
| Triamcinolone | The serum concentration of Triamcinolone can be decreased when it is combined with Dabrafenib. |
| Triazolam | The serum concentration of Triazolam can be decreased when it is combined with Dabrafenib. |
| Triclabendazole | The serum concentration of Triclabendazole can be decreased when it is combined with Dabrafenib. |
| Trifluridine | The excretion of Trifluridine can be decreased when combined with Dabrafenib. |
| Trilaciclib | Dabrafenib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. |
| Trimebutine | The serum concentration of Trimebutine can be decreased when it is combined with Dabrafenib. |
| Trimethadione | The serum concentration of Trimethadione can be decreased when it is combined with Dabrafenib. |
| Trimethoprim | The serum concentration of Trimethoprim can be decreased when it is combined with Dabrafenib. |
| Trimipramine | The serum concentration of Trimipramine can be decreased when it is combined with Dabrafenib. |
| Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Dabrafenib. |
| Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dabrafenib. |
| Troglitazone | The serum concentration of Troglitazone can be decreased when it is combined with Dabrafenib. |
| Troleandomycin | The serum concentration of Dabrafenib can be increased when it is combined with Troleandomycin. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Trovafloxacin. |
| Tucatinib | The metabolism of Tucatinib can be decreased when combined with Dabrafenib. |
| Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Dabrafenib. |
| Udenafil | The serum concentration of Udenafil can be decreased when it is combined with Dabrafenib. |
| Ulipristal | The serum concentration of Ulipristal can be decreased when it is combined with Dabrafenib. |
| Umbralisib | The serum concentration of Dabrafenib can be increased when it is combined with Umbralisib. |
| Umeclidinium | The serum concentration of Dabrafenib can be increased when it is combined with Umeclidinium. |
| Upadacitinib | The serum concentration of Upadacitinib can be decreased when it is combined with Dabrafenib. |
| Valaciclovir | The excretion of Valaciclovir can be decreased when combined with Dabrafenib. |
| Valbenazine | The serum concentration of Valbenazine can be decreased when it is combined with Dabrafenib. |
| Valdecoxib | The serum concentration of Valdecoxib can be decreased when it is combined with Dabrafenib. |
| Valproic acid | The serum concentration of Valproic acid can be decreased when it is combined with Dabrafenib. |
| Valsartan | The serum concentration of Valsartan can be decreased when it is combined with Dabrafenib. |
| Vandetanib | The serum concentration of Vandetanib can be decreased when it is combined with Dabrafenib. |
| Vardenafil | The metabolism of Vardenafil can be decreased when combined with Dabrafenib. |
| Varenicline | The excretion of Varenicline can be decreased when combined with Dabrafenib. |
| Velpatasvir | The serum concentration of Velpatasvir can be decreased when it is combined with Dabrafenib. |
| Vemurafenib | The serum concentration of Dabrafenib can be increased when it is combined with Vemurafenib. |
| Venetoclax | The serum concentration of Venetoclax can be decreased when it is combined with Dabrafenib. |
| Venlafaxine | The serum concentration of Venlafaxine can be decreased when it is combined with Dabrafenib. |
| Verapamil | The serum concentration of Verapamil can be decreased when it is combined with Dabrafenib. |
| Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Dabrafenib. |
| Verteporfin | Dabrafenib may increase the photosensitizing activities of Verteporfin. |
| Vilanterol | The serum concentration of Vilanterol can be decreased when it is combined with Dabrafenib. |
| Vilazodone | The serum concentration of Vilazodone can be decreased when it is combined with Dabrafenib. |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dabrafenib. |
| Viloxazine | The metabolism of Dabrafenib can be decreased when combined with Viloxazine. |
| Vinblastine | The serum concentration of Vinblastine can be decreased when it is combined with Dabrafenib. |
| Vincristine | The serum concentration of Vincristine can be decreased when it is combined with Dabrafenib. |
| Vindesine | The serum concentration of Vindesine can be decreased when it is combined with Dabrafenib. |
| Vinflunine | The serum concentration of Vinflunine can be decreased when it is combined with Dabrafenib. |
| Vinorelbine | The serum concentration of Vinorelbine can be decreased when it is combined with Dabrafenib. |
| Vismodegib | The serum concentration of Vismodegib can be decreased when it is combined with Dabrafenib. |
| Vitamin D | The serum concentration of Vitamin D can be decreased when it is combined with Dabrafenib. |
| Vitamin E | The serum concentration of Vitamin E can be decreased when it is combined with Dabrafenib. |
| Voclosporin | The serum concentration of Dabrafenib can be increased when it is combined with Voclosporin. |
| Vonoprazan | Vonoprazan can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Vorapaxar | The serum concentration of Vorapaxar can be decreased when it is combined with Dabrafenib. |
| Voriconazole | The serum concentration of Voriconazole can be decreased when it is combined with Dabrafenib. |
| Vorinostat | The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Dabrafenib. |
| Vortioxetine | The serum concentration of Vortioxetine can be decreased when it is combined with Dabrafenib. |
| Voxelotor | The serum concentration of Dabrafenib can be increased when it is combined with Voxelotor. |
| Voxilaprevir | The serum concentration of Voxilaprevir can be decreased when it is combined with Dabrafenib. |
| Warfarin | The serum concentration of Warfarin can be decreased when it is combined with Dabrafenib. |
| Ximelagatran | The serum concentration of Ximelagatran can be decreased when it is combined with Dabrafenib. |
| Yohimbine | The serum concentration of Yohimbine can be decreased when it is combined with Dabrafenib. |
| Zafirlukast | The serum concentration of Zafirlukast can be decreased when it is combined with Dabrafenib. |
| Zalcitabine | The excretion of Zalcitabine can be decreased when combined with Dabrafenib. |
| Zaleplon | The serum concentration of Zaleplon can be decreased when it is combined with Dabrafenib. |
| Zanubrutinib | The serum concentration of Zanubrutinib can be decreased when it is combined with Dabrafenib. |
| Zidovudine | The serum concentration of Zidovudine can be decreased when it is combined with Dabrafenib. |
| Zileuton | The serum concentration of Zileuton can be decreased when it is combined with Dabrafenib. |
| Zimelidine | The metabolism of Dabrafenib can be decreased when combined with Zimelidine. |
| Ziprasidone | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ziprasidone. |
| Zolmitriptan | The metabolism of Zolmitriptan can be decreased when combined with Dabrafenib. |
| Zolpidem | The serum concentration of Zolpidem can be decreased when it is combined with Dabrafenib. |
| Zonisamide | The serum concentration of Zonisamide can be decreased when it is combined with Dabrafenib. |
| Zopiclone | The serum concentration of Zopiclone can be decreased when it is combined with Dabrafenib. |
| Zotepine | The serum concentration of Zotepine can be decreased when it is combined with Dabrafenib. |
| Zuclopenthixol | The serum concentration of Zuclopenthixol can be decreased when it is combined with Dabrafenib. |
Drug-Food Interactions
- Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum levels of dabrafenib.
- Avoid St. John’s Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of dabrafenib.
- Do not take with or immediately after a high-fat meal. Dabrafenib’s bioavailability is reduced when taken with a high-fat meal.
- Take on an empty stomach. Take dabrafenib at least one hour before or two hours after a meal.
Pregnancy and Lactation
AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.
Pregnancy
Based on animal studies, this drug may cause fetal harm and impair fertility. This drug may decrease the efficacy of hormonal contraceptives; counsel female patients of reproductive potential to use an effective non-hormonal method of contraception during therapy and for 2 to 4 weeks after the last dose of this drug and 4 months after the last dose of trametinib when given in combination with this drug. Advise male patients of the potential risk for impaired spermatogenesis, which may be irreversible. Adequate methods of contraception should be encouraged. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
Lactation
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
How should this medicine be used?
Dabrafenib comes as a capsule to take by mouth. It is usually taken twice a day on an empty stomach, 1 hour before or 2 hours after a meal. Take dabrafenib about 12 hours apart at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take dabrafenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Do not stop taking dabrafenib without talking to your doctor.
Swallow the capsules whole; do not open, break, or crush them.
Your doctor may adjust your dose or temporarily or permanently stop your treatment depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment.
Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with dabrafenib and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide.
What special precautions should I follow?
Before taking dabrafenib,
- tell your doctor and pharmacist if you are allergic to dabrafenib, any other medications, or any of the ingredients in dabrafenib capsules. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in PrevPac); dexamethasone; gemfibrozil (Lopid); ketoconazole; midazolam; nefazodone; rifampin (Rifadin, in Rifamate, in Rifater, Rimactane); and warfarin (Coumadin, Jantoven). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with dabrafenib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor if you have or have ever had diabetes; glucose-6-phosphate dehydrogenase (G6PD) deficiency (a genetic condition); bleeding problems; eye problems; heart failure or other heart problems; liver or kidney disease; or any other medical condition.
- tell your doctor if you are pregnant or plan to become pregnant, or if you plan to father a child. If you are female, you will need to have a pregnancy test before you start treatment, and you should use effective birth control to prevent pregnancy during your treatment and for 2 weeks after your final dose. If you are a male and your partner can become pregnant, you should use a condom while taking this medication, and for 2 weeks after your treatment, even if you have had a vasectomy (surgery to prevent sperm from leaving your body and causing pregnancy). You should know that this medication may decrease fertility in men and women; however, you should not assume that you cannot get pregnant or that you cannot get someone else pregnant. If you or your partner becomes pregnant while taking dabrafenib, call your doctor. Dabrafenib may harm the fetus.
- you should know that dabrafenib may decrease the effectiveness of hormonal contraceptives (birth control pills, patches, rings, implants, and injections). You should use another method of birth control to prevent pregnancy in yourself or your partner during your treatment with dabrafenib and for 2 weeks after your final dose. Talk to your doctor about birth control methods that will work for you.
- tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while taking dabrafenib and for 2 weeks after your final dose.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking dabrafenib.
References
